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1. Executive Summary 
 
1.1. General background 
 
Multiple Sclerosis (MS), a leading cause of neurodisability, is a chronic inflammatory 
disorder of the central nervous system (Thompson, Baranzini, Geurts, Hemmer, & 
Ciccarelli, 2018). The condition causes changes including sensation, mobility, balance, 
sphincter, vision and cognition symptoms (Brownlee, Hardy, Fazekas, & Miller, 2017). 
Although there is no cure for MS, disease-modifying drugs (DMDs) can significantly 
reduce relapse rates and disease progression (Fogarty, Schmitz, Tubridy, Walsh, & 
Barry, 2016). People with MS face a difficult decision when it comes to weighing up 
the various costs and benefits of DMDs as the complex risk-benefit profiles are not 
always correctly interpreted and understood by people with MS (Reen, Silber, & 
Langdon, 2017a).  
 
Additional support may be required when making decisions in these situations as people 
with MS have been shown to make different decisions in the context of risk (Sepulveda 
et al., 2017). Under explicit risk conditions, MS patients show greater risk aversion and 
deficits on tasks which probe the anticipated effects of decision outcomes on future 
choices (Simioni et al., 2012). This study highlighted that the quality of decision-
making under risk was different for MS patients. 
 
It is important that patients are able to understand the complex risk and benefit 
information surrounding DMDs, which include serious and even fatal side effects, so 
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that they are better able to make decisions about their treatment. Shared decision-
making as part of a patient-centred approach has been advocated as the pinnacle of 
patient-centred care (Barry & Edgman-Levitan, 2012); patient understanding is a 
prerequisite for successful shared decision-making. Shared decision-making is 
associated with better DMD adherence rates in MS, this is critical as the efficacy of 
DMDs depends on high levels of adherence (Ben-Zacharia et al., 2018).  
 
Reen and colleagues developed a protocol: the Benefit and Risk Information for 
Medication in Multiple Sclerosis (BRIMMS), in order to improve patients’ 
understanding and certainty about treatment (Reen, Silber, & Langdon, 2017b). The 
researchers found that the BRIMMS improved patients’ understanding and confidence 
in treatment decisions, compared to standard presentation of treatment information used 
in the UK. 
 
An individual’s risk attitude, risk perception and propensity are important factors that 
may influence the treatment decision-making process. Once the effect of risk attitude, 
perception and propensity on treatment understanding and decision certainty is known, 
characteristics of the patients could be determined in advance of the consultation during 
which the information is presented. The information could be amended to support the 
shared decision-making process. A recent systematic review looking at methods to 
investigate patient preferences for treatment identified the influence of risk perception 
and uncertainty on treatment decisions as neglected research topics (Webb et al., 2018).  
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1.2. Systematic Review 
 
The literature suggests that an individual’s risk attitude, risk perception and risk 
propensity may have an impact on decision-making. Interest in this area is justified 
given that risk information could be used to tailor communication in the shared 
decision-making process, to accommodate patient risk characteristics.  
 
A systematic review was conducted to investigate MS patients’ risk perception, risk 
attitude, risk tolerance/acceptance and risk knowledge across studies, and consider how 
this relates to patient treatment decisions. 
 
Online literature databases were systematically reviewed for relevant articles. The 
inclusion criteria consisted of peer-reviewed studies in English, with human adult 
patients with any clinical subtype of MS. No date restriction was applied. Studies were 
required to have a quantitative design. Studies were included if they reported an 
evaluation related to risk perception, risk attitude, risk tolerance/acceptance or risk 
knowledge in patients with MS. 
 
Data on participants, study characteristics and key findings were extracted and 
summarised. A total of 19 studies were included, containing data from 13,054 patients 
(76% were female), who presented with a range of MS disease subtypes. The mean age 
of patients ranged from 36.50 years to 55.10 years. Most studies used hypothetical 
scenarios to assess risk. Two studies included a cognitive measure. Five studies 
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measured mood using the Hospital Anxiety and Depression. A quality rating tool was 
used to assess study methodology.  
 
Patients tended to overestimate the short-term risks of MS and underestimate the long-
term risks. They had a tendency to rate the general risk as higher than the risk they 
attribute to themselves. Overall, risk knowledge was low and the results regarding risk 
attitude were mixed. The more risk-seeking an individual, the more likely they were to 
choose no treatment. A limitation of the systematic review is the difficultly with which 
robust conclusions can be drawn, given that the studies used a variety of different 
methods to assess risk. It could be suggested that a more consistent way of defining and 
measuring the different elements of risk in MS is required. There was also variation 
between the studies in terms of study design and patient characteristics. This limits the 
ability to draw generalisable conclusions and reflects a lack of uniformity across studies 
that address risk in MS. 
 
1.3. Empirical Study 
 
The primary aim of the study was to confirm the finding that BRIMMS is superior to 
standard presentation in improving patients’ understanding scores and increasing patient 
certainty in decisions.  
 
Ethical approval was obtained from the Health Research Authority (Reference: 
18/NI/0102) and certified by Royal Holloway Research Ethics Committee. The 
inclusion criteria were: all participants (a) were fluent in English; (b) were aged 
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between 18 and 65 years; (c) had a diagnosis of Relapsing-Remitting MS (RRMS) by a 
Consultant Neurologist based on Thompson et al., (2018) criteria; (d) were able to give 
informed consent; (e) were able to meet the task demands of the experiment in terms of 
sensorimotor abilities. The exclusion criteria were: (a) significant changes in medication 
or condition within the last four weeks; (b) a history of significant psychiatric disorders, 
substance or alcohol abuse; (c) significant medical condition (other than MS), personal 
or social circumstances that were likely to impact on participating in the study; (d) 
significant visual, motor or hearing impairments that would have an impact on their 
engagement with the tests/protocol/questionnaires. 
 
The hypotheses of the study were: (1) the BRIMMS protocol would improve patients’ 
understanding of treatment risks and benefits compared to standard consultation; (2) the 
BRIMMS protocol would reduce patients’ conflict regarding treatment decisions 
compared to standard consultation; (3) the BRIMMS would be rated more positively by 
patients than the standard consultation; (4) Self-reported risk attitude (Glanz et al., 
2016), perception (Glanz et al., 2016) and propensity to take risks (Bechara, Damasio, 
Damasio, & Anderson, 1994) would predict patient and patient certainty in treatment 
decisions. 
 
Participants were provided with a hypothetical clinical trial scenario where the 
treatment benefits were stipulated for the intervention group (those taking the treatment) 
and a placebo group (those not taking any treatment). Each patient received treatment 
risks and benefits presented in both the BRIMMS format, and also standard consultation 
format as a control condition. Understanding of treatment risks and benefits was 
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assessed by asking fifteen comprehension questions regarding the side-effects, adverse 
risks and benefits of each hypothetical treatment. Three feedback questions were asked 
at the end of each condition. The Decisional Conflict Scale (O’Connor, 1995), a self-
reported questionnaire, was used to assess patients’ decisional conflicts regarding their 
treatment options. After being presented with each set of treatments, patients were 
required to make a decision regarding treatment (i.e. choose one of the two hypothetical 
treatments, choose neither or say that there were unsure). 
 
Risk was measured by a single-item measure of risk orientation (Maestas & Pollock, 
2010), the Risk Propensity Scale (RPS; Meertens & Lion, 2008), a standard gambling 
scenario (Glanz et al., 2016) and the Iowa Gambling Task (IGT; Bechara, Damasio, 
Damasio, & Anderson, 1994). Patients were also asked to estimate the likelihood of 
becoming wheelchair-bound over the short (two years), medium (five years) and long-
term (ten years), on a five-point scale (ranging from extremely unlikely to extremely 
likely).  
 
Some measures and questionnaires were included to benchmark the sample. That is, to 
ensure that the sample was typical of other published MS samples. Premorbid 
intellectual functioning was assessed using The Wechsler Test of Adult Reading 
(WTAR; Wechsler, 2001). Cognition was examined using The Brief International 
Cognitive Assessment for MS (BICAMS; Langdon et al., 2012). Perceived fatigue was 
measured by the Fatigue Severity Scale (FSS; Krupp, LaRocca, Muir-Nash, & Steinber, 
1989). Self-reported depression and anxiety were assessed using the Hospital Anxiety 
and Depression Scale (HADS; Zigmond & Snaith, 1983). 
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The study had a within-subjects design. Using G*Power (Faul, Erdfelder, Lang, & 
Buchner, 2007) the specified sample size was 46, with an alpha at .05, with a power of 
.80.  
 
Due to recruitment being slower than expected, 26 participants were recruited. The 
majority of the sample was female (n = 19; 73 %), with a mean age of 43.38 (SD = 
10.32) and a mean average pre-morbid intelligence quotient (IQ) of 101.65 (SD = 
14.09). Scores on the HADS were consistent with previously published means for 
HADS in the MS population (HADS-D: M = 4.58, SD = 3.87; HADS-A: M = 7.96, SD 
= 4.40). Years since diagnosis ranged from 1-26 years (M = 9.35, SD = 6.50). The 
average age of diagnosis was 33.70 years, which is in line with previously reported data. 
Expanded Disability Status Scale (EDSS; Kurtzke, 1983) scores ranged from 0-7 (M = 
2.81, SD = 2.45). 10 (39%) participants were impaired on the Symbol Digit Modalities 
Test (SDMT), 7 (27%) were impaired on the California Verbal Learning Task II 
(CVLT-II) and 8 (31%) were impaired on the Brief Visuospatial Memory Test- Revised 
(BVMT-R). When comparing the sample means with published norms, the current 
sample was consistent with previous norms (Bichuetti et al., 2018; Heesen et al., 2017; 
Orchard, Giovannoni, & Langdon, 2013). 
 
There was support for the first hypothesis that the BRIMMS protocol would improve 
patients’ understanding of treatment risks and benefits compared to standard 
consultation. An Analysis of variance (ANOVA) showed that there was a significant 
overall difference between conditions (F(1, 25) = 3388.83,  p < .001), demonstrating 
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that patients’ understanding was significantly higher after the BRIMMS condition (M = 
27.58; SD = 1.67), than after the standard consultation (M = 3.35; SD = 1.29). However, 
the effect of condition was non-significant after controlling for depression (F(1, 22) = 
.44, p = .517) and fatigue (F(1, 22) = .35, p - .558). 
 
A repeated measures ANOVA confirmed the second hypothesis that the BRIMMS 
protocol reduced patients’ decisional conflict compared to standard consultation (F(1, 
25) = 10.78, p = .003). Mean score for the BRIMMS was 24.21 (SD = 14.91). And 
mean score for the standard consultation was 38.28 (SD = 17.32). The third hypothesis 
that the BRIMMS would be rated more positively by patients than the standard 
consultation was not supported. A repeated measures ANOVA revealed no significant 
effect of consultation on patient feedback (F(1, 25) = .94, p .339). Mean score for the 
BRIMMS was 7.22 (SD = 2.07) and mean score for the standard consultation was 6.55 
(SD = 2.59). 
 
There was no evidence for the fourth and fifth hypotheses regarding associations 
between self-reported risk attitude, perception, propensity to take risks and 
understanding or decisional conflict.  
 
Several limitations were noted. Firstly, the use of hypothetical disease and treatments 
raises the possibility that the findings may not apply to the understanding of real DMD 
risks and benefits, in that the information was not personally relevant. The study could 
have benefited from a more robust design where each patient receives two different 
hypothetical diseases, each with two different hypothetical treatments. 
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In summary, the BRIMMS is associated with better patient understanding of treatment 
risks and benefits and reduced decisional conflict, compared to standard consultation. 
However, differences in understanding scores may be explained by either fatigue or 
depression. It is recommended that the BRIMMS should be further evaluated and 
implemented in real consultation in a clinical setting.  
 
1.4. Integration, Impact and Dissemination  
 
The integration of the two components serves to provide a narrative around the need for 
patients to understand the risks and benefits associated with the DMDs, in order to 
approve adherence. The thesis is well linked to various government notes (“PN 500”, 
2017), reports (The Academy of Medical Sciences, 2017) and international initiatives 
(Rieckmann et al., 2018). These sources stipulate that effective communication of the 
evidence regarding the benefits, risks and uncertainty of treatments in a way that is 
clear, accessible and usable so that patients can make sense of it is a key priority for 
research. The results of the systematic review demonstrate that patients tend to 
overestimate the short-term risks of the disease and underestimate the long-term risks. 
MS patients have a tendency to rate the general risk as higher than the risk they attribute 
to themselves. The more risk-seeking an individual, the more likely they are to choose 
no treatment. The findings of the empirical study suggest that the BRIMMS is a tool 
that could be used in order to improve the shared decision-making process around 
DMDs.  
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2. Systematic Review 
 
What do Multiple Sclerosis patients perceive about the risks of Multiple Sclerosis: 
A systematic review 
 
2.1. Abstract 
 
Multiple Sclerosis (MS) is a chronic inflammatory disorder of the central nervous 
system, which often results in neurological disability. Disease modifying drugs have the 
potential to reduce the number of relapses and delay the progression of the disease. The 
different and complex risk-benefit profiles of the drugs need to be effectively 
communicated to people with MS, which is not always achieved. Additional support 
may be required when making decisions in these situations as people with MS have 
been shown to make different decisions in the context of risk. Under explicit risk 
conditions, MS patients show a greater risk aversion and deficits on tasks which probe 
the anticipated effects of decision outcomes on future choices. The aim of this 
systematic review was to evaluate MS patient’s risk perception, risk attitude, risk 
tolerance/acceptance and risk knowledge across studies, and consider how this relates to 
patient treatment decisions. A literature search was performed in PubMed, Web of 
Science and PsycINFO in March 2019. The Effective Public Health Practice Project 
quality assessment tool for quantitative studies was used to examine the quality of the 
studies. 19 studies met the inclusion criteria. Data from  
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13,054 MS patients were included in the review. The results showed that patients 
overestimate the benefits of treatment, overall risk knowledge is low and the results 
regarding risk attitude are mixed. The more risk-seeking an individual the more likely 
they are to choose no treatment. Overall, a greater understanding of a patients’ risk 
profile (risk perception, risk attitude, risk knowledge and risk tolerance/acceptance) is 
important for shared decision-making. Taking this information into account could lead 
to greater satisfaction with treatment choice and greater adherence. It might be possible 
to assess patients on a variety of risk variables and tailor communication to support and 
accommodate their particular risk profile.  
 
2.2. Introduction 
 
Multiple Sclerosis (MS) affects approximately 2.3 million people worldwide 
(Thompson, Baranzini, Geurts, Hemmer, & Ciccarelli, 2018). MS is a chronic 
inflammatory disorder of the central nervous system, which often results in neurological 
disability (Dutta & Trapp, 2014). The condition causes changes in sensation, mobility, 
balance, sphincter activity, vision and cognition (Brownlee, Hardy, Fazekas, & Miller, 
2017).  
 
Most people with MS initially experience Relapsing Remitting MS (RRMS) followed 
by Secondary Progressive MS (SPMS), the latter is a disease course characterised by 
disability progression, with more frequent exacerbations with little or no improvement 
(Stadelmann, Wegner, & Bruck, 2011). It has been suggested that the switch from 
RRMS to SPMS occurs about 10-15 years after onset (Leray et al., 2010; Scalfari et al., 
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2010). Disability associated with SPMS affects various functions such as gait, balance, 
vision, cognition and continence (Rovaris et al., 2006). The most common functional 
consequence of MS is mobility problems. This affects 50% of those diagnosed within 
15 years of disease onset (Noseworthy, Lucchinetti, Rodriguez, & Weinshenker, 2000). 
For those with RRMS, the median time from diagnosis to requiring a wheelchair for 
mobility is 28 years (Scalfari et al., 2010). This first attack of MS is referred to as a 
clinically isolated syndrome (CIS). However, some patients present with a gradual 
progressive course without a clearly defined initial attack; this is termed Primary 
Progressive MS (PPMS). The least common type of MS is Progressive Relapsing MS 
(PRMS), which is characterised by a gradually worsening state from the start, with 
acute relapses. 
 
Disease modifying drugs (DMDs) have the potential to reduce the number of relapses 
and delay the progression of the disease (Vargas & Tyor, 2017). The treatments that MS 
patients are often initially offered, first-line DMDs, have good long-term safety profiles 
and limited adverse risks, however they are only moderately successful (Auricchio et 
al., 2017). If the initial treatments are not effective, or the disease is aggressive from the 
start, second-line DMDs may be offered. These DMDs have higher efficacy, but 
potentially more frequent serious adverse effects, including leukemia, cardiotoxicity, 
and progressive multifocal leukoencephalopathy (Torkildsen, Myhr, & Bo, 2016).  
 
The different and complex risk-benefit profiles of the drugs need to be effectively 
communicated to people with MS, which is not always achieved (Reen, Silber, & 
Langdon, 2017a). Shared decision-making in health care is accepted as the optimal 
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approach for treatment decisions (Elwyn et al., 2012; Barry, 2012). Additional support 
may be required when making decisions in these situations as people with MS have 
been shown to make different decisions in the context of risk (Sepulveda et al., 2017).  
 
Some decisions are made in situations that offer explicit information about the possible 
consequences of making a certain decision, therefore requiring people to choose 
between the alternative concrete options, which are associated with different rewards 
and punishments (Simioni et al., 2012). Under these explicit risk conditions, MS 
patients show a greater risk aversion and deficits on tasks which probe the anticipated 
effects of decision outcomes on future choices (Simioni et al., 2012). Patients also 
differed from controls in the quality of their decision-making on a gambling task; they 
selected the most favourable odds less often than controls and also had longer 
deliberation times before choosing an option. This study highlighted that the quality of 
decision-making under risk was different for MS patients.  
 
An individual’s risk perception, risk attitude/risk propensity, risk knowledge and risk 
tolerance/acceptance are important characteristics that may influence their treatment 
decisions. “Risk perception” is defined as one’s subjective judgments and interpretation 
about risk, e.g. about the likelihood of negative outcomes such as illness, injury and 
death (Paek & Hove, 2017). Risk perception is a very individual assessment and is 
likely to be affected by personal experience. Disease risk perceptions are critical in 
determining health behaviour (Ferrer & Klein, 2015). “Risk attitude” is a construct that 
characterizes an individual’s decision-making in terms of taking or avoiding risk when 
deciding how to proceed under conditions of uncertainty (Rosen, Tsai, & Downs, 2003). 
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The term “risk propensity” is often used in the same way to describe an individual’s 
current tendency to take or avoid risk (Sitkin & Weingart, 1995). Risk attitude/risk 
propensity are explicit estimated of a behaviour or risk-related action. “Risk 
knowledge” in the context of medical decision-making refers to the determinants, 
inheritance, prognosis and the risks and benefits of treatments (Gigerenzer & Gray, 
2013).  Risk knowledge refers to known or understood information (factual and 
detailed), which is less likely to be influenced by personal experience and emotion. An 
additional relevant characteristic is individual willingness to acceptance certain risks 
associated with treatments: “risk tolerance or acceptance”. This gives a detailed 
estimate of risks that would be taken as a result of certain behaviours or actions 
(treatment choice), but this time in the context of a treatment benefit. Something bad is 
going to happen (illness related), therefore the risks of treatment are weighed against 
treatment benefit. Doing nothing has a cost in this instance. 
 
 
Some researchers have argued that the concept of risk perception is complex and vague. 
They have suggested that instead, it should be collectively termed “risk judgment” 
because this includes cognitive, affective, and behavioural dimensions as well as 
perceptual elements (Dunwoody & Neuwirth, 1991). The emphasis on the rational and 
cognitive aspects of risk perceptions can be seen in health behaviour theories such as 
the Health Behaviour Model (HBM). The HBM is based on the assumption that people 
want to avoid illness and will therefore engage behaviours which they believe will 
protect them from illness (Paek & Hove, 2017). The HBM includes four categories of 
risk perception, which are thought to be precursors to health behaviour: perceived 
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susceptibility, perceived severity, perceived benefits, and perceived barriers (Paek & 
Hove, 2017). “Perceived susceptibility” refers to people’s subjective beliefs regarding 
their vulnerability and how susceptible they are to a disease/other health risk. The 
model also includes “perceived severity”: how serious one believes a health risk is, and 
whether the risk would result in adverse consequences such as ostracism, stigma, and 
shame. “Perceived benefits” refers to beliefs about whether health behaviours will 
manage health risks. “Perceived barriers” refers to one’s beliefs about the costs or 
negative aspects of engaging in a health behaviour and whether these will prevent one 
doing so (Peak & Hove, 2017). 
 
Some researchers have argued that more dimensions of risk perception need to be 
explored. A meta-analysis suggests including “perceived likelihood”, which refers to 
the probability that one will be harmed by a risk (Brewer, Chapman, Gibbons, & 
McCaul, 2007).  The authors reviewed 34 studies and “perceived likelihood” seemed to 
be a distinct component of risk perception, which was consistently related to health 
behaviour. In addition, it is important to note that there is often a difference between 
patients and healthcare professionals regarding perceived acceptable DMD risks 
(Kremer, Evers, Jongen, & Hiligsmann, 2018). 
 
Over the last decade, several oral and monoclonal antibody therapies have been licenced 
for MS (See Figure 1). DMDs are only effective in the relapsing forms of MS, with the 
exception of Ocrelizumab (licenced for PPMS) and Siponimod (licenced for SPMS). 
The mechanisms of how DMDs work are not fully understood. It is thought that by 
constraining the dysregulated immune system, DMDs may limit the inflammation of the 
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nervous system, preventing relapses and new inflammatory lesions (De Angelis, John, 
& Brownlee, 2018).  
 
Natalizumab, a monoclonal antibody, is one of the most effective treatments currently 
available for RRMS (Yaldizli & Putzki, 2009). Monthly intravenous injections are 
generally well tolerated, with the exception of rare hypersensitivity reactions (O’Connor 
et al., 2014). Natalizumab is associated with an increased risk of developing progressive 
multifocal leukoencephalopathy (PML). PML is an opportunistic, disabling and 
potentially life-threatening disease caused by the John Cunningham Virus (JCV). Prior 
to commencing treatment, all patients should be screened for previous JCV infection. 
The estimated risk for PML in JCV-negative patients is low (0.1/1000; Pavlovic, Patera, 
Nyberg, Gerber, & Liu, 2015). Amongst JCV-positive patients, the risk of developing 
PML is influenced by the treatment duration and previous immunosuppressive 
treatment. Risk is relatively low during the first two years of treatment and increases 
thereafter. Patients are monitored throughout treatment for JCV, PML and other safety 
considerations (Clerico et al., 2017). 
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Figure 1. Timeline depicting the approval of DMDs for MS by the Food and Drug 
Administration and the European Medicine Agency. Reprinted from “Disease-
modifying therapies for multiple sclerosis”, by F. De Angelis, N. John and W. 
Brownlee, 2018, BMJ, 363, p. 10.  
 
Mitoxantrone is rarely used in MS and is administered via infusion, which is usually 
repeated once every three months for two years and is generally well tolerated in 
patients with MS. The short-term most frequent adverse events documented have been 
nausea/vomiting (62%), alopecia (47%) and increased risk of infection, mostly urinary 
tract infections (25%) and respiratory tract infections (35%), especially in patients with 
little mobility (Martinelli, Radaelli, Straffi, Rodegher, & Comi, 2009). The most serious 
risks of are cardiotoxicity and therapy-related acute leukaemia (TRAL). Cardiotoxicity 
is present in 0.25-0.50% of patients and has been found to be related to dosage (Ghalie, 
et al., 2002). In order to minimise this risk, patients receive cardiac function testing 
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every six months. A review of the literature found that TRAL was diagnosed in 0.73% 
of the 12,896 patients identified (Ellis, Brown, & Boggild, 2015).  
 
Patients with MS are challenged making decisions under risk conditions. They present 
with an atypical profile when it comes to health risk. These aspects might have an 
influence on how well they are able to simulate and process risk information that they 
are given about DMDs, because it is known that the different and complex risk-benefit 
profiles of the drugs are not always correctly understood by patients with MS (Reen et 
al., 2017a). 
 
There are several aspects of risk that could affect how MS patients perceive and manage 
their illness. Firstly, risk directly related to disease process and secondly in relation to 
risk of DMDs. There is also a question regarding how individual or group 
characteristics may influence this (risk attitude/risk tolerance).  
 
Research questions: 
1) How do patients with MS perceive the risk of MS severity? 
2) How do patients with MS perceive the risk of wheelchair dependency?  
3) How do patients with MS perceive the risks of DMD treatment?  
4) What is risk attitude of patients with MS?  
5) What is risk knowledge of patients with MS?  
6) What is risk tolerance/acceptance of patients with MS? 
 
The literature suggests that an individual’s risk attitude, perception and propensity may 
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have an impact on decision-making. Interest in this area is justified because risk 
information could be used to tailor communication which facilitates shared decision 
making, to accommodate patient risk characteristics.  
 
To the best of our knowledge, the present review is the first with the primary aim of 
evaluating MS patients’ risk perception, risk attitude, risk tolerance/acceptance and risk 
knowledge across studies, and to consider how this relates to patient treatment 
decisions. 
 
2.3. Methods 
 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses  (PRISMA) 
recommendations were used as a guide for the reporting of information in this review 
(Moher, Liberati, Tetzlaff, Altman, & The PRISMA Group, 2009). A protocol for the 
present review was not previously published or registered.   
 
2.3.1. Systematic literature search 
 
The systematic literature search was conducted in March 2019 using PubMed, Web of 
Science and PsycINFO using specific search terms (See Table 1). After removing 
duplicate studies, a total of 118 records were identified (See Figure 2).  
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Table 1 
Search terms for systematic review 
 
(Multiple AND sclerosis) 
 
AND 
 
(Patients OR patient OR persons OR people OR individuals OR individual 
 
AND 
 
(Risk perception OR risk attitude OR risk knowledge OR risk propensity OR risk attitudes 
OR risk perceptions OR perception of risk OR risk tolerance OR risk acceptance) 
 
 
2.3.2. Eligibility criteria 
 
The inclusion criteria consisted of peer-reviewed studies in English, with human adult 
patients with any clinical subtype of MS. No date restriction was applied. Studies were 
required to have a quantitative design. Qualitative studies were not included in this 
review due to the potential epistemological differences between qualitative and 
quantitative research, which suggests that they warrant separate synthesis. Studies were 
included if they included an evaluation related to risk perception, risk attitude, risk 
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tolerance/acceptance or risk knowledge in patients with MS. All titles and abstracts 
were screened. At this stage, 19 studies were considered for eligibility and full texts 
were accessed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. PRISMA flow chart for selection process of studies.  
 
 
Records screened 
(n=90) 
Records excluded following 
exclusion criteria 
(n= 70) 
Studies included in review 
(n= 19) 
Full-text articles excluded, with 
reasons  
(n=1) 
-no baseline data reported 
 
 
 
 
Records after duplicates removed 
 (n=90) 
Full-text articles assessed for 
eligibility 
(n=20) 
 
Records identified through database 
searching 
 (n=118) 
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2.3.3. Data extraction  
 
Data extraction forms were created to extract relevant information from the full texts, 
and assess their eligibility for the final review. Extraction was carried out by one 
reviewer (ED) and verified by another (DL). Any discrepancies were resolved by 
discussion. Following data extraction, 70 studies were excluded from the final review 
due to the exclusion criteria. 
 
Baseline characteristics of MS patients were extracted from the shortlisted studies (See 
Table 2). This included (where reported) age, gender, type of MS, disease duration, time 
since diagnosis and The Expanded Disability Status Scale (EDSS; Kurtzke, 1983) and 
Patient Determined Disease Steps (PDDS; Hohol, Orva, & Weiner, 1995). Information 
was recorded regarding whether or not the study had a control group, as well as any 
cognitive measures undertaken by the patients (including measures of mood). Any data 
available on assessing risk perception, risk attitude, risk tolerance/acceptance and risk 
knowledge of patients was retained, including how risk was measured and the outcome 
of such studies.  
 
2.3.4. Quality assessment 
 
The Effective Public Health Practice Project (EPHPP) quality assessment tool for 
quantitative studies was used to examine the quality of the studies (Thomas, Ciliska, 
Dobbins, & Micucci, 2004). The EPHPP tool was chosen because it is often used to 
evaluate studies in a health care setting, it has a high inter-rater reliability (Armijo-
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Olivo, Stiles, Hagen, Biondo, & Cummings, 2012) and is considered useful when 
conducting a systematic review (Deeks et al., 2003).  The final quality rating was based 
on selection bias, study design, confounders, blinding, data collection method, and 
withdrawals and drop-outs (See Table 3). 
 
 
2.4. Results 
 
2.4.1. Study design and participant demographics   
 
19 studies were identified in the review, most of which used a questionnaire design. 
Control data was collected in five of the studies (Prosser & Wittenberg, 2007; Tur et al., 
2013; Kopke et al., 2014; Bsteh et al., 2017; Kopke et al., 2017). Two of the nineteen 
studies were considered to be of a strong quality, with three studies considered to be of 
a moderate quality and the remaining fourteen studies were considered to be of a weak 
quality according to the EPHPP Quality Assessment Tool. It is important to use the 
EPHPP as a standardised means to assess study quality. 
 
Across the 19 studies, a total of 13,054 MS patients were included with a range of MS 
disease subtypes:  0.30% (45) CIS patients, 38% (4,992) RRMS patients, 3% (368) 
SPMS patients, 1.50% (191) PPMS patients and 0.10% (7) PRMS patients. The 
remaining 57% of patients had unclear or unreported MS disease subtype. The mean 
age of patients ranged from 36.50 to 55.10 years. One study stated the median age as 40 
years (Kopke et al., 2014).  Of the 13,054 patients, 76% (9,934) were female and 23% 
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(3,024) were male. One study including 1% (96) of the total patients did not specify 
gender (Bichuetti et al., 2018).  
 
Five studies reported time since first symptom (Janssens et al., 2003; Janssens et al., 
2004; Kopke et al., 2014; Glanz et al., 2016; Heesen et al., 2017) with a range from 3.70 
years to 15.50 years. 16 studies reported patients’ mean time since diagnosis (Janssens 
et al., 2003; Janssens et al., 2004; Heesen, Kasper, Segal, Köpke, & Mühlhauser, 2004; 
Heesen et al., 2010; Hofmann et al., 2012; Tur et al., 2013; Kopke et al., 2014; Fox et 
al., 2015; Kopke et al., 2017; Bichuetti et al., 2018; Bsteh et al., 2017; Heesen et al., 
2017; Bruce et al., 2018a; Bruce et al., 2018b; Giordano et al., 2018; Fox et al., 2019) 
with a range from 7.80 months to 16.60 years. Two studies did not specify either time 
since first symptom or time since diagnosis (Prosser, Kuntz, Bar-Or, & Weinstein, 
2002; Prosser et al., 2007). Four studies gave both time since diagnosis and time since 
first symptom (Janssens et al., 2003; Janssens et al., 2004; Kopke et al., 2014; Heesen et 
al., 2017). 
 
11 of the 19 studies reported an EDSS, a measure of neurological disability, five 
reported the mean EDSS and six reported the median EDSS. The median EDSS ranged 
from 1.50 (no disability, minimal signs in more than one functional system) to 4.00 
(significant disability but self-sufficient and up and about some 12 hours a day and able 
to walk without aid or rest for 500m; Janssens et al., 2003; Janssens et al., 2004; Heesen 
et al., 2010; Tur et al., 2013; Glanz et al., 2016; Bsteh et al., 2017). The mean EDSS 
ranged from 2.60 (mild disability in one functional system or minimal disability in two 
functional systems) to 3.70 (moderate disability in one functional system and more than 
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minimal disability in several others and no impairment to walking; Prosser et al., 2002; 
Prosser et al., 2007; Bichuetti et al., 2018; Heesen et al., 2017; Kopke et al., 2017). Four 
studies reported PDDS score, which is a self-reported outcome measure used in MS that 
strongly correlates with the EDSS (Learmonth, Moti, Sandroff, & Cadavid, 2013). 
Scores on the PDDS vary from 0 (normal) to 8 (bedridden). Three studies reported the 
mean, ranging from 1.67 (which corresponds to mild/moderate disability with limited 
gait abnormality) to 3.20 (which corresponds to gait disability, occasionally requiring 
assistance to walk; Fox et al., 2015; Bruce et al., 2018a; Bruce et al., 2018b). One study 
reported the median PDSS as 3 (Fox et al., 2019). 
 
Two studies included a cognitive measure (Heesen et al., 2017; Bruce et al., 2018b). 
Patients were assessed on the Symbol Digit Modalities Test (SDMT), a test of 
information processing speed and data was available for 441 of the 801 patients. 35% of 
patients were considered to have a cognitive deficit (as indicated by a test results 1.50 
standard deviations below that of an age matched control group; Heesen et al., 2017). 
Bruce et al., (2018b) created a cognitive composite score by using SDMT, The Rey 
Auditory Learning Test (verbal learning) and Trails B (executive skills). Higher score 
represent better cognitive functioning. Mean cognitive composite score was -0.0018 
(SD=0.77; range -3.26 to 1.65). The authors reported that only two patients scored 
below -2, indicating cognitive impairment. 
 
One study included the Beck Depression Inventory-II (BDI-II; Beck, Steer & Brown, 
1996) as a screen for symptoms of depression; four patients had a score ≥ 18 indicating 
a clinical level of depression (Bsteh et al., 2017). Qualitatively, these patients also 
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reported higher burden of disease and a stronger subjective loss of health. Depressed 
patients did not differ significantly from patients without depression in terms of risk 
behaviour. Four studies measured mood using the HADS (Janssens et al., 2004; Kopke 
et al., 2014; Kopke et al., 2017; Bruce et al., 2018b). Patients with higher disability 
reported significantly more symptoms of anxiety and depression. 34% of patients had 
clinically relevant levels of anxiety and 10% of depression (>8 on HADS; Janssens et 
al., 2004). Mean scores on the HADS were low at baseline (Anxiety = 7.00 ± 3.60 for 
the intervention group and 7.00 ± 3.70 for the control group; Depression = 4.10 ± 3.80 
for the intervention group and 4.80 ± 4.10 for the control group; Kopke et al., 2014). 
Bruce et al. (2018b) reported slightly higher rates with a mean overall score of 11.62 on 
the HADS. Disease related distress was measured by the Impact of Events Scale (IES; 
Horowitz, Wilner, & Alvarez, 1979) in one study (Janssens et al., 2004). Patients with 
more disability were significantly more distressed, researchers found a positive 
correlation between EDSS and intrusion and avoidance on the IES. 
  
The studies identified examined different aspects of risk in MS. In order to compare and 
critique, the studies were grouped as follows: firstly, risk perception of disease and 
disability (perceived risk of disease severity/perceived risk of wheelchair dependency); 
secondly, risk perception of DMD treatment; thirdly, risk knowledge and fourthly, 
individual risk tolerance/acceptance.  
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Study (first 
author, year) 
Quality 
Rating 
Methodological 
design 
IG=Intervention 
group 
CG=Control 
group 
Recruitment 
method 
Sample 
size 
Gender 
(n) 
Female=F 
Male=M 
Age in 
years  
Type of MS (n) 
CIS=Clinically 
Isolated Syndrome 
RRMS=Relapsing-
Remitting MS 
SPMS=Secondary-
Progressive MS 
PPMS=Primary-
Progressive MS 
PRMS=Progressive-
Relapsing MS 
 
Time since 
first 
symptom  
 
Time 
since 
diagnosis 
EDSS score 
unless 
stated 
otherwise 
On 
treatment 
Prosser, 
2002 
Weak Survey MS clinic over 
a 6 month 
period 
56 44 (F) 
12 (M) 
38.00 
(mean) 
RRMS (56) - - 3.70 
(mean) 
33 
Janssens, 
2003 
Weak Questionnaire 
and interview 
MS clinic 101 70 (F) 
31 (M) 
37.50 
(mean) 
Unspecified (101) 3.70 years 
(mean) 
 
7.80 
months 
(mean) 
2.50 
(median) 
- 
Janssens, 
2004 
Weak Questionnaire MS clinic 101 70 (F) 
31 (M) 
37.50 
(mean) 
Unspecified (101) 3.70years 
(mean) 
 
7.80 
months 
(mean) 
2.50 
(median) 
- 
Heesen, 
2004 
Moderate Postal 
questionnaire-
observational 
study 
 
Randomly 
selected from 
outpatient 
register 
169 106 (F) 
 63 (M) 
44.00 
(mean) 
RRMS (75); 
PPMS (75); 
Unspecified (19) 
- 7.70 years 
(mean) 
- 103 
Table 2 
Study design and patient demographics 
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Study (first 
author, year) 
Quality 
Rating 
Methodological 
design 
IG=Intervention 
group 
CG=Control 
group 
Recruitment 
method 
Sample 
size 
Gender 
(n) 
Female=F 
Male=M 
Age in 
years  
Type of MS (n) 
CIS=Clinically 
Isolated Syndrome 
RRMS=Relapsing-
Remitting MS 
SPMS=Secondary-
Progressive MS 
PPMS=Primary-
Progressive MS 
PRMS=Progressive-
Relapsing MS 
 
Time since 
first 
symptom  
 
Time 
since 
diagnosis 
EDSS score 
unless 
stated 
otherwise 
On 
treatment 
Prosser, 
2007 
Weak Survey and 
control group 
MS clinic and 
residents in 
San Diego 
56 44 (F) 
12 (M) 
38.00 
(mean) 
RRMS (56) - - 3.70 
(mean) 
- 
Heesen, 
2010 
Moderate Questionnaire MS clinic 69 45 (F) 
24 (M) 
40 .00 
(median) 
Unspecified (69) - 11.00 
years 
(median) 
4.00 
(median) 
64 
Hofmann, 
2012 
Weak Retrospective 
cohort study 
Database from 
university 
medical 
centre, 
hospitals and 
one private 
practice 
 
 
575 371 (F) 
204 (M) 
50.30 
(mean) 
RRMS (49); 
SPMS (258); 
PPMS (76); 
Other/unknown 
(192) 
- 14.30 
years 
(median) 
- 53 
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Study (first 
author, year) 
Quality 
Rating 
Methodological 
design 
IG=Intervention 
group 
CG=Control 
group 
Recruitment 
method 
Sample 
size 
Gender 
(n) 
Female=F 
Male=M 
Age in 
years  
Type of MS (n) 
CIS=Clinically 
Isolated Syndrome 
RRMS=Relapsing-
Remitting MS 
SPMS=Secondary-
Progressive MS 
PPMS=Primary-
Progressive MS 
PRMS=Progressive-
Relapsing MS 
 
Time since 
first 
symptom  
 
Time 
since 
diagnosis 
EDSS score 
unless 
stated 
otherwise 
On 
treatment 
Tur, 
2013 
Weak Survey 
Natalizumab 
treated (IG) 
Other DMD 
(CG) 
MS centre 136 IG 80 (F) 
     34 (M) 
CG 16(F) 
      6 (M) 
IG 37.78 
(mean) 
CG 39.16 
(mean) 
- - IG 12.92 
(mean) 
CG 5.21 
(mean)             
IG 3.75 
(median)  
CG 2.00 
(median) 
136 
Kopke, 
2014 
Strong 12 m, 6 centre, 
double-blind 
RCT Baseline 
data. 4hr 
interactive 
education (IG) 
vs stress 
management 
(CG) 
MS clinic 192 IG 69 (F) 
     24 (M) 
 
CG 74(F) 
      25(M) 
IG 36.50 
(mean) 
CG 36.70 
(mean) 
CIS (27); 
RRMS (133); 
Unclear (32) 
IG (4.30 
years; 
mean) 
CG (4.00 
years; 
mean)  
 
IG (1.40 
years; 
mean) 
CG (1.20 
years; 
mean) 
- 41 (IG) 
45 (CG) 
Fox, 
2015 
Weak Questionnaire MS registry 5446 4250 (F) 
1196 (M) 
52.70 
(mean) 
- - 13.90 
(mean) 
3.20 
(mean-
PDDS) 
3700  
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Study (first 
author, year) 
Quality 
Rating 
Methodological 
design 
IG=Intervention 
group 
CG=Control 
group 
Recruitment 
method 
Sample 
size 
Gender 
(n) 
Female=F 
Male=M 
Age in 
years  
Type of MS (n) 
CIS=Clinically 
Isolated Syndrome 
RRMS=Relapsing-
Remitting MS 
SPMS=Secondary-
Progressive MS 
PPMS=Primary-
Progressive MS 
PRMS=Progressive-
Relapsing MS 
 
Time since 
first 
symptom  
 
Time 
since 
diagnosis 
EDSS score 
unless 
stated 
otherwise 
On 
treatment 
Glanz, 
2016 
Weak Questionnaire MS centre 223 173 (F) 
50 (M) 
49.30 
(mean) 
CIS (13); 
RRMS (158); 
SPMS (44); 
PPMS (5); 
PRMS (3) 
15.50 years 
(mean) 
- 1.50 
(median) 
165  
Bichuetti, 
2018 
Weak Questionnaire MS clinic 96 Did not 
specify 
39.30 
(mean) 
RRMS (96) - 9.10 years 
(mean) 
2.60 
(mean) 
94 
Bsteh, 
2017 
Weak Questionnaire 
compared to 
published 
norms. 
MS clinic 22 15 (F) 
7  (M) 
42.30 
(mean) 
RRMS (17); 
SPMS (3); 
PPMS (2) 
- 9.00 years 
(mean) 
2.50 
(median) 
16 
Heesen, 
2017 
Moderate Multi-centre 
non-
interventional 
observational 
study. 
MS clinic and 
private 
practice  
801 562 (F) 
239 (M) 
38.60 
(mean) 
RRMS (801) 10.20 years 
(mean) 
 
8.70 years 
(mean) 
3.10 
(mean) 
801 
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Study (first 
author, year) 
Quality 
Rating 
Methodological 
design 
IG=Intervention 
group 
CG=Control 
group 
Recruitment 
method 
Sample 
size 
Gender 
(n) 
Female=F 
Male=M 
Age in 
years  
Type of MS (n) 
CIS=Clinically 
Isolated Syndrome 
RRMS=Relapsing-
Remitting MS 
SPMS=Secondary-
Progressive MS 
PPMS=Primary-
Progressive MS 
PRMS=Progressive-
Relapsing MS 
 
Time since 
first 
symptom  
 
Time 
since 
diagnosis 
EDSS score 
unless 
stated 
otherwise 
On 
treatment 
Kopke, 
2017 
Strong Controlled 
rater-blinded. 
Two cohorts 
separated by 
time (2months).  
CG=standard 
care. IG 
=patient 
information 
programme 
Neurological 
rehabilitation 
centres 
156 IG 62 (F) 
     13(M) 
 
CG 55(F) 
      26(M) 
IG 
(42.20; 
mean) 
CG 
(42.50; 
mean) 
CIS (5); 
RRMS (105); 
SPMS (14); 
PPMS (13); 
Other/unknown (19) 
- IG (7.00 
years; 
mean) 
CG (9 .00 
years; 
mean) 
IG 3.30 
(mean) 
CG 3.40 
(mean) 
40 (IG) 
48 (CG) 
Bruce, 
2018a 
Weak Questionnaire MS clinic, 
online, letters 
and MS 
newsletter 
290 232 (F) 
58 (M) 
49.28 
(mean) 
RRMS (217) 
SPMS (49) 
PPMS (20) 
PRMS (4) 
- 11.97 
years 
(mean) 
2.40  
(mean 
PDDS) 
190 
Bruce, 
2018b 
Weak Questionnaire MS clinic, via 
advertisements 
and via MS 
newsletter 
208 173 (F) 
35 (M) 
46.02 
(mean) 
RRMS 208 - 11.00 
years 
(mean) 
1.67  
(mean 
PDDS) 
167 
 43 
Study (first 
author, year) 
Quality 
Rating 
Methodological 
design 
IG=Intervention 
group 
CG=Control 
group 
Recruitment 
method 
Sample 
size 
Gender 
(n) 
Female=F 
Male=M 
Age in 
years  
Type of MS (n) 
CIS=Clinically 
Isolated Syndrome 
RRMS=Relapsing-
Remitting MS 
SPMS=Secondary-
Progressive MS 
PPMS=Primary-
Progressive MS 
PRMS=Progressive-
Relapsing MS 
 
Time since 
first 
symptom  
 
Time 
since 
diagnosis 
EDSS score 
unless 
stated 
otherwise 
On 
treatment 
Giordano, 
2018 
Weak Survey (in 8 
countries) 
Online 986 
 
755 (F) 
231 (M) 
38.60 
(mean) 
RRMS (986) 
 
- 7.80 years 
(mean) 
- - 
Fox, 
2019 
Weak Survey MS registry 3371 2668 (F) 
703 (M) 
55.10 
(mean) 
RRMS (2035) 
Other (1331) 
- 16.60 
years 
(mean) 
3.00 
(median 
PDDS) 
1798  
TOTAL    13,054 9934(F) 
3024(M) 
96 (Did 
not 
specify) 
 CIS (45) 
RRMS (4992) 
SPMS (368) 
PPMS (191) 
PRMS (7) 
Other/unknown 
(7451) 
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Overall quality rating: Strong=no weak ratings; Moderate=one weak rating; Weak=two or more weak ratings. 
 
Study (first 
author, year) 
Selection 
bias 
Study 
design 
Confounders Blinding Data 
collection 
method 
Withdrawals 
and dropout  
Overall 
quality 
rating 
Prosser, 2002 Moderate Weak Weak Weak Weak N/A Weak 
Janssens, 2003 Moderate Weak Weak Weak Moderate N/A Weak 
Janssens, 2004 Moderate Weak Weak Weak Moderate N/A Weak 
Heesen, 2004 Moderate Weak Weak Moderate Strong Moderate Moderate 
Prosser, 2007 Moderate Weak Weak Weak Weak N/A Weak 
Heesen, 2010 Moderate Moderate Moderate Weak Moderate N/A Moderate 
Hofmann, 2012 Weak Moderate Weak Moderate Weak Weak Weak 
Tur, 2013 Moderate Strong Moderate Weak Weak N/A Weak 
Kopke, 2014 Strong Strong Strong Strong Strong Strong Strong 
Fox, 2015 Moderate Weak Weak Weak Weak N/A  Weak 
Glanz, 2016 Moderate Weak Weak Weak Moderate N/A Weak 
Bichuetti, 2018 Moderate Weak Weak Weak Moderate N/A Weak 
Bsteh, 2017 Moderate  Weak Weak Weak Strong N/A Weak 
Heesen, 2017 Moderate Moderate Moderate Weak Moderate N/A Moderate 
Kopke, 2017 Moderate Strong Strong Moderate Strong Strong Strong 
Bruce, 2018a Moderate Weak Weak Weak Moderate N/A Weak 
Bruce, 2018b Moderate Weak Weak Weak Moderate N/A Weak 
Giordano, 2018 Moderate Weak Weak Weak Moderate N/A Weak 
Fox, 2019 Moderate Weak Weak Weak Weak N/A Weak 
Table 3  
Quality assessment of studies that have included measures of risk in MS patients 
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2.4.2. Risk perception  
 
Risk perception refers to one’s subjective judgments and interpretation about risk, e.g. 
the likelihood of negative outcomes such as illness, injury and death (Paek & Hove, 
2017). 
 
2.4.2.1 Risk perception of disease severity  
 
Perceived risk of severity of MS was assessed in four studies (Heesen et al., 2010; Tur 
et al., 2013; Heesen et al., 2017; Bichuetti et al., 2018) using a visual analogue scale 
(VAS). A VAS is a commonly used method to measure subjective experience of 
constructs such as pain, fatigue and anxiety. A VAS is usually presented as a single 
100mm line with anchor words at each end of the scale (e.g. no pain-worst imaginable 
pain). The VAS does not have gradations and is considered to be more sensitive than 
scales with intermediate marks; patients are not bound to predefined categories, but 
rather given the opportunity to place themselves at one point along a continuum 
(Hjermstad et al., 2011). A number of studies have suggested that a VAS is a reliable 
and valid technique (Remington, Tyrer, Newson-Smith, & Cicchetti, 1979; Hasson & 
Arnetz, 2005).  
 
Patients were asked to rate the extent to which they perceived MS to be a severe disease 
(See Table 4). Patients considered their own disease to be less severe than they rated 
MS risk for patients in general (Tur et al., 2013). Broadly similar predictive variables 
within a multiple regression model were sex, age and EDSS. Men rated MS as more 
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severe (ß = -0.10, p = 0.02), the perception of severity increased with age (ß = 0.10, p = 
0.02), as well as with increased disability (ß = 0.13, p = 0.00; Heesen et al., 2017).  
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Table 4     
Risk perception of disease severity     
     
Study VAS  design           Mean IG 
 
Mean CG SD Median Interquartile range 
Heesen, 2010 Range 0-10
a 
       -  - 8.50 6.50-9.50 
Tur, 2013 Range 0-10   7.00  (general) 
  5.77 (individual)
b
 
7.62 (general) 
6.10 (individual) 
- - - 
Bichuetti, 2018 Range 0-10   7.30 
 
 +/-2.40 - - 
Heesen, 2017 Range 1-25
c
  18.60  - - - 
Note. SD=Standard Deviation. IG=Intervention Group. CG=Control Group 
a0=MS is not at all a severe disease; 10=MS is the most severe disease you can think of 
bTwo scores were obtained, one in general (for MS patients as a whole) and one for individual (in their particular case) 
c1=benign; 25=severe. 
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Whilst all three studies yielded similar results, a possible disadvantage of using a VAS 
is that patients may have difficulty finding the point that is most applicable to them 
(Duncan, Bushnell, & Lavigne, 1989).  
 
 
2.4.2.2. Perceived risk and perceived seriousness of wheelchair dependency  
 
The course of MS is largely unpredictable and uncertain, with serious consequences, 
such as wheelchair dependency. Patients’ perceived risk of wheelchair dependency was 
assessed using a VAS (Janssens et al., 2003; Janssens et al., 2004) and a 5-point scale 
(Glanz et al., 2016). Patients’ perceived seriousness of becoming wheelchair dependent 
was assessed using a VAS (Janssens et al., 2003). Patients rated seriousness of 
wheelchair dependency after two years, ten years and for a lifetime, with the VAS 
points anchored at ‘not serious at all (0)’ and ‘the most serious thing I can imagine’ 
(100). Wheelchair dependency was defined as the inability to walk more than five 
metres. Likelihood and seriousness of each patients’ wheelchair dependency was 
measured on a VAS over the short (two years), medium (ten years) and long-term 
(lifetime; Janssens et al., 2003), with its points anchored at ‘definitely not (0%)’ and 
‘definitely (100%)’. Actual risks were derived from epidemiological data and estimated 
to be 5-10% for two year risk, 20-25% for ten year risk and 70-80% for lifetime risk 
(Weinsheker, 1989). Glanz et al. (2016) asked patients to estimate the likelihood that 
they would become wheelchair dependent in two years (short), five years (medium) and 
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ten years (long-term) on a five point scale, ranging from extremely unlikely to 
extremely likely.  
 
When compared to the epidemiological data (data based on the distribution and 
determinants in the MS population) patients overestimated their two and ten year risk of 
wheelchair dependency, but underestimated their lifetime risk (Janssens et al., 2003). 
One-third of patients perceived the ten year or lifetime risk to be about 50%. A more 
qualitative exploration was conducted by interviewing patients about their perception of 
the ten year risk. Results from these interviews indicated that these “50%” responders 
reported significantly more uncertainty than the remaining two-thirds of patients. 
Explanations like ‘l don’t know’ (3.80-fold increase compared with others, p < 0.001) 
and ‘It might happen, or it might not happen’ (30-fold increase compared with others,            
p < 0.001) were used significantly more often by the “50%” responders. Patients who 
had more functional limitations (as measured by the EDSS) perceived themselves to be 
at higher risk of wheelchair dependency at each time point. Perceptions of risk were not 
related to sex, age, diagnostic certainty (definite versus probable MS) or time since 
diagnosis/first symptoms.  
 
Similar percentages of patients reported that their risk of MS worsening over the next 
two, five and ten years was likely/extremely likely (18.80%, 34.80% and 52.20%, 
respectively; Glanz et al., 2016). Patients with a higher EDSS, or a progressive disease 
course, perceived themselves to be at higher risk of progression at each time interval. 
Patients with a higher relapse rate over the last year rated the risk of progression at ten 
years to be more likely, but not at two or five years. 
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Patients considered wheelchair dependency a serious consequence of their disease at all 
time points (two years: mean VAS = 82.50, SD = 19.70; ten years: mean VAS = 74.50, 
SD = 22.90; lifetime: mean VAS = 71.60, SD = 24.00). Patients with more disability 
perceived wheelchair dependency to be less serious ( p <0.01). Perceptions of risk were 
not related to sex, age, diagnostic certainty (definite versus probable MS), time since 
first symptom or time since diagnosis. 
 
Janssens et al. (2003) suggested that differences in functional ability alter the need and 
significance of a wheelchair and its seriousness. Patients with limited walking ability 
may see a wheelchair as a means to increase their mobility, where as those who are 
currently fully mobile, may perceive a wheelchair as a more serious consequence. The 
findings of this study are limited by its small sample size. 
 
Janssens et al. (2004) investigated the impact of perceived risk of wheelchair 
dependency on anxiety, depression and disease-related distress. After controlling for 
EDSS, time since first symptoms, time since diagnosis, age and sex, authors found that 
patients with higher perception of risk and seriousness of wheelchair dependency were 
more distressed by intrusions of MS-related thoughts and feelings. This relationship was 
found for two year, ten year and lifetime risk of wheelchair dependency. Only the two 
year risk and seriousness of wheelchair dependency was related to anxiety and 
depression. The results need to be interpreted with caution given that this is the first 
study to use the IES to assess psychological distress related to the diagnosis of a chronic 
disease. The reliability and validity of using such measure in this population could be 
questioned.  
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In terms of generalisability, patients in Janssens et al. (2003) had all been diagnosed 
within the two years prior to the study, however the sample investigated by Glanz et al. 
(2016) were an average of 15.50 years from onset, therefore reflective of a broader, 
more generalisable sample.  
 
Taken together these findings indicate that patients have high levels of uncertainty 
regarding risk of wheelchair dependency and raise the question whether the perception 
of prognostic risks can be improved in the clinical setting.  
 
2.4.2.3. Risk perception in treatment  
 
MS drugs have different and complex risk-benefit profiles (Angelis et al., 2018). The 
perceived likelihood of benefits and risks related to the medication taken for MS was 
assessed in four studies using a range of methods including a VAS (Heesen et al., 2010; 
Heesen et al., 2017), a 5-point scale (Glanz et al., 2016) and multiple-choice questions 
(Hofmann et al., 2012).  
 
To assess perceived efficacy of Natalizumab, patients were asked to estimate how many 
patients taking/not taking Natalizumab would be wheelchair dependent within ten years 
and how many patients would not be able to walk more than 100m. Patients were given 
eleven multiple-choice answers for both questions, answers were presented as follows: 
<10, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 of 100 treated patients (Heesen et al., 2010).  
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General PML risk was assessed using a VAS, with its points anchored at 0=no risk and 
10=high risk (Heesen et al., 2010). Similarly, Heesen et al. (2017) used a VAS to ask 
patients about their perceived general PML risk, ranging from 1=low, to 25=high.  
 
General PML risk was perceived as moderate (mean VAS = 4.5; Heesen et al., 2010; 
mean VAS = 11; Heesen et al., 2017). Overall, patients overestimated the benefit of 
Natalizumab (Heesen et al., 2010). A multiple regression model indicated that the 
perception of general PML risk was higher in women. Patients who had lived with MS 
for a long time and received Natalizumab for a long time perceived the general risk as 
lower (Heesen et al., 2017).  Given this finding it was suggested that patients may have 
to some degree adapted to the risks of treatments (Heesen et al., 2017). 
 
Another study used a VAS to assess general risk perception of Mitoxantrone and 
perception of individual risk for leukaemia (an adverse risk associated with the 
medication; Hofmann et al., 2012). Points on the VAS were anchored at 0 (low risk) 
and 10 (high risk). Patients perceived the general risk of Mitoxantrone as significantly 
higher than the risk patients attributed to themselves (Hofmann et al., 2012). Hoffman et 
al. (2012) suggest that the results from their study are reflective of people with MS 
having an optimistic bias in their own personal risk attribution compared to the general 
risk perception.  
 
Glanz et al. (2016) asked patients to estimate the minor and serious side effects of 
commonly prescribed MS drugs on a five point scale, ranging from extremely unlikely 
to extremely likely. Interestingly, when asked to estimate the minor and serious side 
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effects of commonly prescribed MS drugs, patients’ most common response was ‘Don’t 
know’. Patients were unwilling to estimate the risk of side effects related to DMDs that 
they had not been prescribed (Glanz et al., 2016). It was suggested these results may 
indicate that patients with MS do not have enough knowledge about the side effects of 
DMDs to enable sufficient decision-making when it comes to the risks and benefits.   
 
The results need to be considered in the context of a possible selection bias: one study 
did not provide data on reason for exclusion of patients from the final sample (Heesen et 
al., 2017). The results are limited by the study’s moderate response rate and its 
retrospective design (Hoffman et al., 2012).  
 
In summary, the literature suggests that MS patients report uncertainty regarding the 
risks associated with DMDs. Patients perceive the general risk to be higher than the risk 
they attribute to themselves. These results are to be considered in the context of 
methodological limitations.  
 
2.4.3. Risk attitude  
 
Risk attitude is used to describe an individual’s decision-making in terms of taking or 
avoiding risk, when deciding how to proceed under conditions of uncertainty (Rosen et 
al., 2003). Risk attitude was measured in three studies (Prosser et al., 2007; Glanz et al., 
2016; Bsteh et al., 2017).  
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One study recruited patients with MS and measured their general risk attitude by using 
two rating scales in addition to a standard gamble scenario (Glanz et al., 2016). 
Participants were first given a single-item of risk orientation that asked patients to rate 
their overall comfort with taking risks from “extremely comfortable” to “extremely 
uncomfortable” on a five point scale. Participants were then given a Risk Propensity 
Scale (RPS), which is a seven-item self-report measure of an individual’s propensity to 
take general/health and safety risks. Researchers also used a standard gamble scenario 
which asked participants to consider a new MS drug that would enable patients to be 
relapse free, with no worsening of symptoms but a possible side effect was death. 
Participants rated the likelihood that they would take the new drug, if the risk of death 
was either 1:2, 1:10, 1:100, 1:1,000, 1:10,000 or 1:100,000. 
 
The majority of participants were risk neutral on the single-measure of risk orientation. 
In contrast, the mean risk propensity score on the RPS indicated an overall aversion to 
issues related to health and safety (Glanz et al., 2016). 65% of patients reported that 
they were risk adverse when it comes to risks associated with their health. This aversion 
to taking risks related to health was confirmed on the standard gamble scenario: almost 
50% of participants reported that they were unlikely/extremely unlikely to take the drug 
even if the probability of death was 1:100,000.  There were no significant associations 
between risk orientation scores or RPS scores and gender, age, race, marital status, 
EDSS, disease course or relapse rate. On the gamble scenario, males were significantly 
more likely to take treatments that carried risk of death at a risk rate of 1:10,000 or 
1:100,000, than females. Although advantageous to measure risk in three different 
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ways, it is unclear how representative the sample is, as patients were recruited from one 
centre during a five-week period (Glanz et al., 2016).  
 
Another study recruited patients with RRMS and assessed risk attitude using a standard 
gamble question on health outcomes (See Figure 3). The number of relapse-free days in 
Box 2 which causes the subject to choose Box 3, was used as a proxy for the patients 
risk attitude regarding health, authors terms this ‘the certainty equivalent’ (Prosser et al., 
2002). For example, if a person were risk neutral, then their response would be fifteen 
relapse-free days. A risk-averse person would accept Drug B even if the number of 
relapse-free days was less than fifteen. A risk-seeking person would not accept Drug B 
unless the number of relapse-free days was more than fifteen. The mean certainty 
equivalent was 14.6 and the median certainty equivalent was fifteen relapse-free days. 
Seven patients showed extreme risk-averse behaviour, accepting the lowest offer. Ten 
patients showed extreme risk-seeking, accepting the highest offer. Results of a 
multinomial logistic regression revealed that the coefficient for the certainty equivalent 
on health was significant and positive for patients that had never been on treatment. 
This finding suggests that when patients are more risk-seeking they are more likely to 
be in the ‘never-on-treatment group’ compared to the group with ‘excellent adherence’ 
(Prosser et al., 2002).  
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Figure 3. Standard gamble scenario on health outcome. Reprinted from “The 
Relationship between Risk Attitude and Treatment Choice in Patients with Relapsing-
Remitting Multiple Sclerosis”, by L. Prosser, K. Kuntz, A. Bar-Or and M. Weinstein, 
2002, Medical Decision Making, 22(6), p. 508. 
 
Risk attitude was assessed via the Urgency, Premeditation, Perseverance, Sensation 
Seeking, Positive Urgency (UPPS) Impulsive Behaviour Scale and The Domain-
specific risk taking scale and comparing patient scores to published normative controls 
(Bsteh et al., 2017). Patients did not significantly differ from the respective normative 
samples for the UPPS Impulsive Behaviour Scale and the Domain-specific risk taking 
questionnaire. Researchers excluded patients that had severe cognitive problems, which 
limits generalizability (Bsteh et al., 2017). The conclusions need to be interpreted with 
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caution given the small sample size, which limits the power of comparisons between 
samples (Bsteh et al., 2017). 
 
Healthy members of the community (control group) and patients with MS were given 
gamble scenarios, two based on money outcomes and one based on health outcomes 
(See Figure 4). Using a control group allows comparison of how MS patients’ 
perceptions compare to the general population. Patients were predominantly risk neutral 
with respect to health outcomes and risk averse with respect to money outcomes 
(Prosser et al., 2007). There were no differences between MS patients and healthy 
controls. The conclusions need to be interpreted with caution given the small sample 
size (Prosser et al., 2007). The accuracy of the novel method of creating a health metric 
to measure risk by using methods tested with monetary outcomes could be questioned. 
It is also important to draw attention to the fact that only one question was asked 
regarding health, which is a small basis on which to confirm/disconfirm the findings in 
relation to health. 
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Figure 4. Standard gamble scenario on health outcome. Reprinted from “Do Risk 
Attitudes Differ across Domains and Respondent Types”, by L. Prosser and E. 
Wittenberg, 2007, Medical Decision Making, 27(3), p. 283. 
 
In summary, the findings regarding patients’ risk attitude are mixed. One study found 
that patients were risk neutral regarding health outcomes and concluded that there was 
no difference in risk attitude between MS patients and healthy controls (Prosser et al., 
2007). However, other research reports that MS patients have an overall risk aversion to 
issues related to health (Glanz et al., 2016). These discrepancies could be explained by 
the different methods of assessment. Findings suggest that risk attitude may be related 
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to treatment choice; the more risk seeking the individual, the more likely they are to 
choose no treatment (Prosser et al., 2002). It is also important to note the general 
limitation of asking patients to respond to hypothetical treatment scenarios; hypothetical 
decisions might be very different to those made in the real world. 
 
It has been suggested that changes in risk attitude in MS patients could be due to a state 
of ‘transient sickness behaviour’ that is related to an acute relapse rather than persistent 
changes in attitude (Bsteh et al., 2017). Interestingly, one study which excluded patients 
with a relapse within 24 weeks prior to assessment found no difference in risk attitude 
compared to controls (Bsteh et al., 2017).  
 
2.4.4. Risk knowledge  
 
Risk knowledge is necessary to enable patients to make informed choices and it had 
been found to contribute to treatment adherence (Costello, Kennedy, Scanziollo, 2008). 
Nine studies measured risk knowledge about prognosis and treatment by using self-
report questionnaires (Heesen et al., 2004; Hofmann et al., 2012; Heesen et al., 2017; 
Kopke et al., 2014; Kopke et al., 2017;Bichuetti et al., 2018; Bruce et al., 2018a; Bruce 
et al., 2018b; Giordano et al., 2018). Patients were given a 19-item risk knowledge 
questionnaire and a mean knowledge score was calculated based on the correct answers 
(Heesen et al., 2004; Kopke et al., 2014). Giordano et al. (2018) used the same measure 
to investigate risk knowledge but conducted the study in eight countries in order to 
investigate cross-cultural differences in MS risk knowledge. One study assessed 
knowledge of the risk of developing PML by five multiple choice answers, ranging 
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from 1:200 to 1:100,000 and calculating a mean knowledge score (Bichuetti et al., 
2018). Heesen et al. (2017) presented patients with seven multiple choice questions 
about PML risk factors and a mean knowledge score was calculated based on correct 
answers. Hofmann et al. (2012) assessed risk knowledge via a questionnaire that 
contained items such as effects and side effects of treatments. Patients completed a 25-
item multiple choice questionnaire on general MS knowledge (Bruce et al., 2018a; 
Bruce et al., 2018b). 
 
The level of overall risk knowledge regarding treatment was low, with only a small 
percentage of questions answered correctly (Heesen et al., 2004; Kopke et al., 2014; 
Kopke et al., 2017).  Risk knowledge was low in all countries, the mean number of 
correct answers in the sample was 8.70 out of 21, indicating a mean correct score of 
41% (Giordano et al., 2018). Germany and Serbia showed the best results with about 
52% correct answers (Giordano et al., 2018).  
 
Patients generally underestimated the risk associated with Mitoxantrone (Hofmann et 
al., 2012). It has been reported that patients generally understood the risks associated 
with Natalizumab (Bichuetti et al., 2018). However other findings suggest patients 
underestimated the hypothetical risk of PML after two years of therapy (Heesen et al., 
2017).  Variables that were significantly associated with risk knowledge were higher 
education, previous DMD experience and a correct answer to medical data 
interpretation question (Giordano et al., 2018). Higher MS knowledge was associated 
with more willingness to initiate a DMD (Bruce et al., 2018a; Bruce et al., 2018b). 
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Patients with the highest knowledge scores had been diagnosed within the past two 
years (Heesen et al., 2004). It was suggested that risk knowledge depends on the actual 
relevance of the information, which is higher in early stages of MS, when patients are 
making decision about DMDs, with discussion regarding risk occurring at diagnosis.  
 
The findings need to be interpreted in the light of the 20% non-response rate, which 
limits the representativeness of the sample (although the authors note that the 
demographic data of the non-responders did not suggest that they formed a separate 
subgroup) and its retrospective design (Hofmann et al., 2012). One study recruited 
patients across six sites, which increases the likelihood that findings will be 
generalisable. However, the external validity is questionable as recruitment took part 
through academic centres (Kopke et al., 2014). A more recent study addresses this 
limitation by recruiting patients through in and outpatient programmes, minimising 
selection bias (Kopke et al., 2017).  
 
Overall, the findings of these studies suggest that patients with MS have a low level of 
risk knowledge. Some of the research suggests that this leads to patients 
underestimating DMDs risks, whereas one study found that patients generally 
understood the risks. These conclusions need to be interpreted with caution given the 
methodological flaws. 
 
2.4.5. Risk tolerance and risk acceptance  
 
Risk tolerance and risk acceptance were assessed using either hypothetical scenarios 
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(Tur et al., 2013; Bruce et al., 2018a; Bruce et al., 2018b; Fox et al., 2019), real DMD 
information (Heesen et al., 2010; Heesen et al., 2017) or a combination of both (Fox et 
al., 2015; Bichuetti et al., 2018).  
 
Tur et al. (2013) presented patients with five hypothetical scenarios which had different 
associated risks of serious side effects. Patients were asked to what extent they would 
like to continue receiving a drug if the associated annualised risk of a serious side effect 
was 1/2,000,000 (very low), 1/600,000 (low risk), 1/5,000 (intermediate risk), 1/1000 
(high risk) and 1/50 (very high risk). Patients answered using a VAS, with values 
ranging from 0-10 (0=I would not like to continue receiving this drug at all; 10=I would 
like to continue receiving this drug without any doubt). The authors created risk-
acceptance scores (RAS) for each scenario, where higher RAS indicated better 
acceptance of risk. They also averaged RAS for the high and very high-risk scenarios to 
obtain a ‘averaged RAS’ score which indicated the level of acceptance for high and 
very high risk associated with treatments. Patients taking Natalizumab showed 
significantly higher RAS across all five scenarios than patients taking other DMDs, 
suggesting a higher acceptance of risks associated with treatments. Researchers also 
found the higher the risk of the scenario, the lower the RAS. When groups were 
analysed as a whole, there was a trend towards a relationship between higher averaged 
RAS and higher perceived disease severity. 
 
A recent study assessed individual risk by presenting patients with a hypothetical 
therapy with a fixed benefit of 50% reduction in clinical relapse rate and 30% reduction 
in disability progression (Fox et al., 2019). These percentages were chosen as they 
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reflect the efficacy of the majority of current DMDs. A standard gamble scenario was 
used to assess the risk tolerance for each of the 6 risks. The risks were 1) risk of 
infection such as bladder and respiratory, which may occasionally require 
hospitalisation; 2) thyroid injury, which may require lifelong thyroid medication; 3) 
skin rash, which may be serious enough to require hospitalisation; 4) liver injury, which 
may require repeated blood test monitoring; 5) kidney injury, which may require 
lifelong dialysis; and 6) risk of PML, which could be fatal. The odds for each risk were 
changed to identify the maximum risk tolerance for each patient. The lowest anchor 
point was 0 (never take any risk for the benefit) to 1 (will take any risk for the benefit). 
Fox et al. (2019) found that patients reported highest tolerance for infection or thyroid 
complications (median risk tolerance = 1:1,000 for both). The next highest tolerance 
was for skin rash (1:2,000), followed by liver injury (1:10,000). The lowest risk 
tolerance was for both kidney injury and PML (1:1,000,000).  
 
Risk tolerance results indicated that a large proportion of patients were risk averse. Risk 
tolerance is also affected by the precise risk being evaluated. Some side effects are more 
acceptable than others. Across all scenarios, men, younger patients and those with a 
greater disability reported higher tolerance of risk. Those currently taking MS therapy 
reported higher tolerance than those not taking therapy. Patients taking infusion 
therapies reported higher tolerance to all risks and those taking injectables reported 
lower tolerance.  
 
Bruce et al. (2018a) asked patients to indicate their likelihood (0-100%) of taking a 
hypothetical DMD in terms of side effect probabilities (11 values from .10% to 99.90%) 
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and reported medication efficacies (11 values from .10% to 99.90%). Bruce et al. 
(2018b) tested a probability discounting model to explore the independent influences of 
risks and benefits when patients make hypothetical treatment decisions. Patients with a 
primary progressive course reported increased DMD willingness, compared to patients 
with RRMS and SPMS. Patients were less willing to initiate DMD across a range of 
efficacies and side effects if they had never taken a DMD (Bruce et al., 2018a). Bruce et 
al. (2018b) found that high rates of discounting based on risks were associated with 
poor treatment adherence and less disease specific knowledge. High rates of discounting 
benefits were associated with poorer cognitive functioning.  
 
Patients were asked to choose the risk level at which they would stop Natalizumab 
treatment, given different risk probabilities of PML (Heesen et al., 2010; Heesen et al., 
2017). 17% of patients indicated they would stop treatment at an adverse event rate of 
1:10,000 or lower, 54% of patients would stop at an event rate of 1:100 and 29% would 
accept higher risks (Heesen et al., 2010). Heesen et al. (2017) reported similar results 
with 40% of patients indicating that they would accept a PML risk of higher than 
100/1000.  
 
Two standard gamble scenarios were used to assess risk tolerance (Fox et al., 2015). 
One scenario promised a complete and permanent reversal of MS symptoms, but had a 
risk of painless, immediate death in sleep. The second scenario was taking the real-life 
treatment Natalizumab, with risks and benefits as documented in previous clinical trials. 
Starting with a complication risk of 1:1,000 for each scenario, patients were asked if 
they would accept treatment with each degree of risk for the associated benefit. Fox et 
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al. (2015) found that three-quarters of people had a tolerance for risks lower than 
1:1,000, indicating that they were risk averse and not willing to take high risks for 
greater benefits. Patients with greater disability tolerated greater risks for a treatment 
that would either cure or slow disease progression.  
 
Bichuetti et al. (2018) presented patients with the same hypothetical scenarios and same 
method as previous researchers (Tur et al., 2013), in order to calculate a RAS.  In 
addition patients were asked to stipulate the level of risk they considered high enough to 
stop or be unwilling to receive Natlizumab. Patients’ RAS was lower than that of 
patients previously interviewed, suggesting a lack of willingness to take risks with 
hypothetical drugs (Tur et al., 2013; Heesen et al., 2010). The older the patient, the 
more likely there were to accept higher risks (Bichuetti et al., 2018). The ability to take 
risks was not associated with years of education, the authors suggested that this reflects 
that all patients interpreted the questions equally. The fact that years of education was 
not measured in the earlier study may account for the difference in findings. 76% of 
patients considered a PML risk of 1:1,000 would stop them using Natalizumab. This is a 
lower threshold than previously reported (Heesen et al., 2010). 
 
In terms of limitations the sample size of one of the studies is relatively small 
(n = 69), although recruiting from two different outpatient centres ensures that the 
findings are more representative (Heesen et al., 2010). This finding was replicated in a 
more recent study by the same authors, using a larger sample (Heesen et al., 2017). 
Cognition or education was not assessed, therefore it is unclear whether patients fully 
understood the contents and therefore not factoring in their ability to make decisions. 
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Furthermore the RAS is not a validated way to assess risk (Tur et al., 2013). Given that 
the sample of one of the studies was from Brazil, the results may not be generalisable to 
the whole country or beyond, or relevant to a European context (Bichuetti et al., 2018). 
It is also important to note that not all of the studies state whether or not the patients are 
currently taking treatment. This is crucial information, given that it is likely that their 
current situation will impact on decision-making. Some of the drugs have higher risk 
profiles than others; it is important that studies stipulate what the current treatments are 
and ensure that they report any associations. 
 
In summary, the results are mixed in relation to level at which patients are willing to 
accept risks, these results need to be considered with caution due to the limitations 
described.  Although risk tolerance is variable among patients with MS, a large 
proportion are risk averse. Risk acceptance seems to be related to age, disease severity, 
type of MS and current DMD.  
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Janssens, 
2003 
- - - - Perceived 
likelihood and 
seriousness of 
becoming 
wheelchair-
dependent (2 
years, 10 years, 
lifetime) 
measured on a 
VAS. 
 
Patients were 
interviewed 
about their 
perception of 
their 10-year 
risk. 
- - Patients 
overestimated their 
2 year and 10 year 
risks of wheelchair 
dependency, but 
underestimated 
their life time risk. 
Patients considered 
themselves to be at 
higher risk of 
wheelchair 
dependency if they 
had more functional 
limitations.  
 
Wheelchair 
dependency was 
rated a serious 
consequence of MS. 
Patients with more 
functional 
limitations had 
lower perceptions 
of seriousness. 
 
 
 
Table 5 
Outcomes of studies assessing risk 
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Janssens, 
2004 
- - HADS 
IES 
- Perceived 
likelihood and 
seriousness of 
becoming 
wheelchair-
dependent (2 
years, 10 years, 
lifetime) 
measured on a 
VAS. 
 
- - Patients with more 
physical limitations 
had significantly 
higher perception of 
the 2year, 10year 
and lifetime risk of 
wheelchair 
dependence, but 
considered 
wheelchair 
dependence to be 
less serious. 
 
Patients with higher 
disability reported 
significantly more 
symptoms of 
depression and 
anxiety. 34% had 
clinically relevant 
levels of anxiety 
and 10% of 
depression.  
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Heesen, 
2004 
- - - - - MS risk 
knowledge 
questionnaire 
(19-item). 
- Overall, risk 
knowledge was 
low, with only a 
small percentage of 
questions answered 
correctly. Highest 
scores were seen in 
patients who had 
been diagnosed 
within the past 2 
years. 
Prosser, 
2002 
- - - Standard 
gamble 
scenario on 
health 
outcomes. 
- - - More risk seeking, 
less likely to choose 
treatment compared 
with more risk 
adverse patients 
(p<0.01). 
Prosser, 
2007 
Healthy 
members of 
the 
community. 
- - Both groups 
were given 
standard 
gamble 
scenarios, 
two based on 
money and 
one based on 
health 
outcomes. 
- - - Patients were 
predominantly risk 
neutral with respect 
to health outcomes 
and risk averse with 
respect to money. 
No difference in 
response of patients 
and healthy 
controls. 
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Heesen, 
2010 
- - - - Asked to rate 
perceived 
severity of MS 
as a disease on 
a VAS (0-10, 
10=high 
malignancy). 
Asked to 
estimate how 
many 
participants 
with and 
without 
Natalizumab 
would end up 
wheelchair 
dependent in 
10years, using a 
VAS and how 
many people 
would not be 
able to walk 
more than 
100m.Asked to 
rate general risk 
of PML. 
 
- - Patients perceived 
MS to be a severe 
disease. 
 
Patients 
overestimated the 
effects of 
Natalizumab. 
 
Rated PML risk as 
moderate. 
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Hofmann, 
2012 
- - - - VAS to assess 
general 
mitoxantrone 
risk perception 
and individual 
risk. 
Risk 
knowledge and 
awareness 
questionnaire 
including side 
effects of 
treatment and 
disease course. 
- Patients perceived 
general risk was 
significantly higher 
than the risk 
patients attributed 
to themselves.  
 
Underestimation of 
risks associated 
with Mitoxantrone. 
Tur, 
2013 
DMD group  
- 
 
- 
 
- 
Rate perceived 
severity of MS 
as a disease on 
a VAS. Asked 
to rate in 
general and in 
their case. 
 
 VAS to rate 
extent to 
which they 
would 
continue 
receiving a 
drug if 
associated 
annual risk of 
serious 
adverse event 
was very-very 
high. Higher 
RAS indicated 
a better 
acceptance for 
risk. 
Patients considered 
their own disease 
was significantly 
less severe than was 
MS in general. The 
higher the risk the 
hypothetical 
scenario had, the 
lower the RAS. 
Trend towards 
higher RAS and 
higher severity 
perception. Nat 
group has higher 
RAS than control 
group. 
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Kopke, 
2014 
CG=standard 
information 
IG=education 
programme 
- HADS - - Risk 
knowledge was 
assessed using 
a 19-item 
multiple-choice 
questionnaire. 
- Baseline mean 
scores on the 
HADS were low. 
Low level of risk 
knowledge. At 
baseline, overall 
risk knowledge was 
low, with only 32 
out of 93 people in 
the intervention 
group answering 
more than 11 of 19 
questions correctly 
and only 22 of 99 
people in the CG 
answering more 
than 11 of 19 
questions correctly. 
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Fox, 
2015 
- - - - - - Online 
standard 
gamble 
paradigm for 
2 scenarios, 
one offering a 
completed 
cure for MS at 
the risk of 
painless death 
in sleep and 
the other 
offering 
Natalizumab 
with its 
associated 
risks and 
benefits. 
Median risk 
tolerance for both 
scenarios was 
1:10,000. Over 3% 
were willing to take 
any risk for either 
of scenarios. 15-
23% were highly 
risk averse and 
would accept no 
risk. Three-fourths 
of patients had a 
risk tolerance lower 
than 1:1000 for 
both scenarios.  
Disability and 
current treatment 
with Natalizumab 
were strongly 
associated with 
higher risk 
tolerance. 
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Glanz, 
2016 
- - - Single-item 
of risk 
orientation 
that asks 
participants 
to rate their 
overall 
comfort with 
taking risk.  
 
Risk 
Propensity 
Scale-a 7 
item self 
report 
measure of 
individual 
propensity to 
take 
general/health 
and safety 
risks 
 
Standard 
gamble 
scenario 
Perceived 
likelihood of 
becoming 
wheelchair-
dependent (2 
years, 5 years, 
10 years) 
measured on a 
5 point scale, 
ranging from 
extremely 
likely to 
extremely 
unlikely. 
 
Estimated the 
likelihood of 
minor and 
serious side 
effects of 
DMDs.  
 
- - 18.80% of patients 
reported their risk 
of MS worsening 
over in 2 years as 
likely/extremely 
likely, 34.80% in 5 
years and 52.20% 
in 10 years. Those 
with higher 
disability perceived 
themselves to be at 
higher risk of 
progression at 2, 5 
and 10 years. 
 
Uncertainty 
regarding side-
effects associated 
with DMDs. 
 
Participants were 
risk neutral on the 
single measure of 
risk orientation and 
risk averse on 
issues related to 
health and safety.  
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Bichuetti, 
2018 
- - - - Rate perceived 
severity of MS 
as a disease on 
a VAS (0=not 
at all, 10=most 
severe thing I 
can think of). 
 
Mean 
knowledge 
score based on 
correct answers 
to a multiple 
choice 
questionnaire 
about risk. 
- Patients perceived 
MS to be a severe 
disease. 
 
Patients understood 
the risks associated 
with Natalizumab. 
Patients considered 
the risk of PML as 
moderate to high. 
 
Bsteh, 
2017 
Compared 
scores to 
published 
norms. 
- BDI-II Patients were 
given the 
UPPS 
impulsive 
behaviour 
scale and The 
domain 
specific risk 
taking scale. 
- - - Four patients had a 
score of ≥18 
indicating 
depression. These 
patients did not 
differ from patients 
without depression 
in terms of risk 
behaviour. 
No significant 
alterations of risk 
attitude in MS 
patients compared 
to healthy controls.  
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Heesen, 
2017 
- SDMT - - Rate perceived 
severity of MS 
as a disease on 
a VAS 
(1=benign, 
25=severe). 
 
Rate 
seriousness of 
becoming 
wheelchair 
dependent.  
 
Patients were 
asked for their 
assessment of 
PML risk in 
general on a 
VAS (1=low, 
25=high) and 
their perceived 
personal risk. 
7 multiple 
choice 
questions on 
PML risk 
factors were 
presented. 
Mean 
knowledge 
score 
calculated. 
- 35% of patients 
were considered to 
have a cognitive 
deficit. 
 
Patients perceived 
MS to be a severe 
disease. Men 
perceived MS as 
more severe than 
women and 
perception of 
severity increased 
with age as well 
with increased 
disability. 
 
Becoming 
wheelchair bound 
was rated as a 
serious 
complication.  
 
General PML risk 
rated as moderate.  
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Kopke, 
2017 
CG=standard 
information 
IG=education 
programme 
- HADS  - - Risk 
knowledge 
assessed by 
using a risk 
knowledge 
questionnaire. 
A cut-off of 9 
or more correct 
answers was 
defined as 
adequate risk 
knowledge. 
- 14% of intervention 
group and 16% of 
control group had 
adequate risk 
knowledge at 
baseline. Indicating 
a low level of risk 
knowledge. No 
baseline HADS 
score were reported. 
Bruce, 
2018a 
- - - - - Medical 
decision-
making task 
patients 
indicated their 
likelihood (0-
100%) of 
taking a 
hypothetical 
DMD as the 
probability of 
mild side 
effects varied. 
 
 
- Patients with a 
primary progressive 
course reported 
increased DMD 
willingness 
compared to 
patients with 
relapsing-remitting 
and secondary-
progressive courses. 
Patients were less 
willing to initiate 
DMD if they had 
never taken a DMD.  
 
 78 
Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Bruce, 
2018b 
- Cognitive 
composite 
score 
using 
Symbol 
Digit 
Modalities 
Test, The 
Rey 
Auditory 
Learning 
Test, 
Trails B 
HADS - - Medical 
decision-
making task 
(MDMT)- 
patients 
indicated their 
likelihood (0-
100%) of 
taking a 
hypothetical 
DMD as the 
probability of 
mild side 
effects and 
medication 
efficacies 
varied. 
 
MS knowledge 
questionnaire-
25 multiple 
choice 
questions 
 
 
 
 
- High rates of 
discounting based 
on risks were 
associated with 
poor treatment 
adherence and less-
disease specific 
knowledge. High 
rates of discounting 
benefits was 
associated with 
poorer cognitive 
functioning.  
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Giordano, 
2018 
- - -  - Risk 
knowledge 
questionnaire 
(RIKNO) 
Self-assessed 
inventory 
consisting of 
19 multiple-
choice items; a 
total score (0-
21) obtained by 
summing 
correct 
answers. 
 
- Mean number of 
correct answers on 
RIKNO was 8.70 
(SD= 3.50) out of 
21, indicating that 
participants got an 
average of 41% of 
answers correct. 
Indicating that 
overall risk 
knowledge was 
low. Variables 
significantly 
associated with 
RIKNO were 
country, previous 
DMD experience. 
Education and fear 
of wheelchair 
dependency. 
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Study (first 
author, year) 
Control 
group  
Cognitive 
measure 
Mood 
measure 
Risk attitude Risk perception Risk 
knowledge  
Risk 
tolerance/risk 
acceptance  
Results 
Fox, 
2019 
- - - - - - Risk 
preference 
and 
acceptance 
was measured 
by describing 
a hypothetical 
treatment with 
varied 
complications. 
Participants 
exhibited highest 
tolerance for 
injection and 
thyroid injury 
(1:1,000) and the 
least tolerance for 
kidney injury and 
PML (1:1,000,000). 
A large proportion 
were risk averse. 
17-39% were 
unwilling to assume 
any risk for 
beneficial therapy. 
Men were more 
tolerant to risks 
than women. 
Increasing age was 
associated with 
lower risk 
tolerance. 
 81 
2.5. Discussion and conclusion  
 
 
 
2.5.1. Discussion  
 
The present systematic review explored MS patients’ risk perception, risk attitude, risk 
knowledge and risk acceptance/tolerance. Studies included patients with different 
clinical subtypes of MS. Risk was generally addressed using hypothetical scenarios with 
differing risk and benefits, as part of a larger study. Most of the studies had 
methodological issues that make it difficult to draw any firm conclusions. These issues 
are reflected in the scores on the quality assessment tool. 
 
People with MS are faced with the difficult decision of weighing up the complex risk-
benefit profiles of DMDs. When in such situations, a shared-decision making approach 
is deemed as the gold standard. For this to work effectively, it requires understanding of 
the patients’ risk perception, risk attitude, risk knowledge and level of risk that they 
consider acceptable. It might be possible to assess patients on a variety of risk variables 
and tailor the approach to support and accommodate their particular risk profile. If this 
was feasible and then implemented in practice, it could support treatment adherence. 
 
The results will be considered in relation to the research questions.  Whilst MS patients 
perceived MS to be a severe disease (Heesen et al., 2010; Tur et al., 2013; Heesen et al., 
2017; Bichuetti et al., 2018), they perceived their own disease as being less severe 
compared to the general population of people with MS (Tur et al., 2013). 
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Patients overestimated their two and ten year risk of wheelchair dependency, but 
underestimated their lifetime risk (Janssens et al., 2003; Glanz et al., 2016). 
Qualitatively, patients expressed uncertainty regarding their ten year risk. Higher 
perception of risk and seriousness of wheelchair dependency was related to distress and 
the short-term risk was related to anxiety and depression (Janssens et al., 2004). It is 
important that patients understand wheelchair dependency risks, particularly as they 
were related to anxiety and depression. 
 
Regarding the perception of risk associated with treatments, patients tended to 
overestimate the benefits of Natalizumab (Heesen et al., 2010). Perception of risk was 
associated with gender, time since diagnosis and current treatment. Patients perceived 
the general risk of treatment as significantly higher than the risk that they attributed to 
themselves (Hofmann et al., 2012). The overestimation of benefits may lead to 
problems with adherence as people may stop taking drug when they realise that the 
benefits are not as much as they originally thought they were.  
 
The results regarding risk attitude are mixed, people with MS were risk neutral on a 
single measure of risk orientation but demonstrated an overall aversion to issues related 
to health and safety (Glanz et al., 2016).  Another study found that patients were risk 
neutral with respect to health outcomes and risk averse with respect to money outcomes 
(Prosser et al., 2007).  However, it must be noted that researchers are drawing this 
conclusion from one question related to health. The more risk-seeking patients were, 
they more likely they were to choose no treatment (Prosser et al., 2002). People with 
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MS did not differ from controls in terms of risk attitude, which could be explained by 
limitations with study design (Prosser et al., 2007; Bsteh et al., 2017). Given the finding 
that risk attitude was related to treatment choice, it is important to take this into account 
in practice. 
 
Overall, patients’ risk knowledge was not accurate and it was judged by authors to be 
low (Heesen et al., 2004; Kopke et al., 2014; Kopke et al., 2017); this finding was 
present across a range of countries (Giordano et al., 2018). If patients do not have 
sufficient risk knowledge, they are not able to usefully participate in the decision 
making process. The low levels of risk knowledge are concerning, given the finding that 
more risk knowledge is associated with willingness to take a DMD (Bruce et al., 
2018a). Providing patients with information in order to increase their risk knowledge 
could lead to a greater number of patients on or adherent to, DMDs. 
 
Risk tolerance differs according to sex, age, disability level and current DMD (Tur et 
al., 2013; Fox et al., 2015; Bichuetti et al., 2018; Bruce et al., 2018a; Fox et al., 2019). 
A large proportion of MS patients were risk averse (Fox et al., 2015). Risk tolerance is 
affected by the precise risk being evaluated, with some side effects considered more 
acceptable than others (Fox et al., 2019). This highlights the importance of taking into 
account the risks that people with MS consider acceptable, this could result in greater 
satisfaction with treatment choice and therefore impact on adherence.  
 
In terms of cognition, one study reported no association between cognition and risk 
measures (Heesen et al., 2017). Patient uncertainty in relation to taking DMDs was 
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associated with poorer cognitive functioning in the second study (Bruce et al., 2018b). 
A recent systematic review found that cognitive dysfunction, particularly processing 
speed and attention had a negative impact on decision-making (Neuhaus, Calabrese, & 
Annon, 2018). It is therefore crucial that future studies take into account the influence 
of cognition on decision-making. It is important that cognitive functioning is considered 
in the shared-decision making process. Patients with poorer cognition may need 
additional support when evaluating the risks and benefits of DMDs. 
 
Whilst five studies included a measure of mood, only three studies reported results in 
relation to the mood and risk measures. Depressed patients did not differ significantly 
from patients without depression in terms of risk behaviour (Bsteh et al., 2017). Mood 
was not associated with how patients discount treatments based on side-effects (Bruce 
et al., 2018b). Despite the lack of associations between mood and risk measures, it 
would be useful for future studies to a mood measure and report on the association with 
risk. Given that this would be useful information to have in order to tailor information 
according during the shared decision-making process. 
 
Bruce et al. (2018b) extend the traditional HBM but proposing that there are individual 
differences in how patients weigh up treatment risks and benefits. Most patients fall in 
the middle, but some are willing to take even small risk for larger possible benefits. 
Patients who often discounted treatments based on the increased probability of side 
effects also had less MS disease knowledge and worse adherence for treatment.  
 
It is important to note that few studies compared patients with MS to healthy controls. 
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However, the comparison is complex because people with MS have current drug 
therapy and experience of personal decisions. It would have been interesting to see the 
difference in performance between these two groups, given that no one is always 
entirely correct. Also, there are few longitudinal studies, it would be beneficial to assess 
patient risk perception at different stages. Rather than a snap shot of risk, longitudinal 
studies would be more reflective of risk profile over time. It is likely that when trying a 
second drug people are willing to accept more risk as the first one did not work (Fox et 
al., 2019).  
 
Overall, differences in patient characteristics and methodology limit the conclusions 
from such findings. Many of the studies have small sample sizes, low response rates and 
possible selection bias. The studies are largely one centre, recruiting people with MS 
who are in contact with health services. In general, it is hard to make comparisons 
between the studies given the different ways that risk was measured. The validity and 
reliability of assessing risk with self-report and hypothetical scenarios needs to be 
considered. Furthermore, researchers claim they are measuring different elements of 
risk but there is a lot of overlap between the different terms, which makes it difficult to 
categorise the studies effectively. The limitations of using the EPHPP as a tool to assess 
the quality of the studies must be considered. The ‘overall quality rating’ does not 
provide an accurate indication of the overall quality, since two or more ‘weak’ rating 
define a study as being ‘weak’. It is important that future studies include cognitive 
measure and measure of mood, as they are factors that can influence patients risk 
tendencies.  
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2.5.2. Practice implications 
 
The practical implications of this review include the need to consider patients’ risk 
perception, risk attitude, risk knowledge and risk acceptance/tolerance in order to 
facilitate the shared decision-making process. This is particularly important given that 
elements of risk may impact on the long-term adherence to DMDs. It could be 
suggested that there is a need for a international consensus project on a perceived risk 
assessment document, tailored for MS clinics, to inform and optimise education and 
shared decision-making for various risk profiles.  
 
2.5.3. Conclusion 
 
The present review was the first to our knowledge to bring together evidence about the 
risk perception, risk attitude, risk knowledge and risk tolerance/acceptance of people 
with MS. Patients tend to overestimate short-term risks of the disease and underestimate 
the long-term risks. They also have a tendency to perceive their likelihood or severity of 
disease related risks as less likely than those for the general population of people with 
MS. Risk attitude was related to treatment choice. A limitation of the current systematic 
review is the difficultly with which robust conclusions can be drawn given the variety 
of methods used to assess risk. It could be suggested that a more consistent way of 
defining and measuring the different elements of risk in MS is required. There was also 
variation between the studies in terms of study design and patient characteristics. This 
limits the ability to draw conclusions and suggests a lack of uniformity across studies 
that address risk in MS. 
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3. Empirical Study 
 
The effect of risk propensity on treatment understanding and decisions in MS 
patients 
 
 
3.1. Abstract 
 
Multiple Sclerosis (MS) is a chronic inflammatory disorder of the central nervous 
system. Disease-modifying drugs (DMDs) can significantly reduce relapse rates and 
disease progression. People with MS face a difficult decision when weighing up the 
costs and benefits of DMDs. Additional support may be required because people with 
MS have been shown to make different decisions in the context of risk. This study 
aimed to confirm whether the Benefit and Risk Information for Medication in Multiple 
Sclerosis protocol (BRIMMS), is superior to standard presentation in improving 
patients’ understanding of treatments and increasing patient certainty in decisions. The 
study investigated how self-reported and objective risk attitude, risk perception and 
propensity to take risks relate to patient understanding scores and certainty in treatment 
decision. 26 participants were recruited (19 females; 73 %), with a mean age of 42.9 
(SD = 10.2). Participants were provided with hypothetical treatment information via the 
BRIMMS and standard consultation. Understanding of treatment risks and benefits was 
assessed. The Decisional Conflict Scale was used to assess patients’ decisional conflicts 
regarding their treatment options. Risk was assessed using a single-item measure of risk 
orientation, the Risk Propensity Scale, a standard gambling scenario and the Iowa 
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Gambling Task. Cognition, premorbid IQ, mood and fatigue were also assessed. 
BRIMMS significantly improved patient understanding of treatment risks and benefits 
and reduced decisional conflict, compared to standard consultation. However, 
differences in understanding scores were explained by fatigue and depression. There 
were no associations between self-reported risk attitude, perception or propensity to 
take risks, understanding or decisional conflict. It is recommended that the BRIMMS 
should be further evaluated and implemented during consultation in a clinical setting.  
 
3.2. Introduction 
 
Multiple Sclerosis (MS) is a chronic inflammatory disorder of the central nervous 
system, which often results in neurological disability (Thompson, Baranzini, Geurts, 
Hemer, & Ciccarelli, 2018). The condition includes sensation, mobility, balance, 
sphincter, vision and cognition symptoms (Brownlee, Hardy, Fazekas, & Miller 2017). 
MS can be classified into three main subtypes: Relapsing Remitting MS (RRMS), 
Secondary Progressive MS (SPMS) and Primary Progressive MS (PPMS). Most people 
with MS initially experience RRMS, which is characterised by distinct attacks of 
symptoms followed by either partial or complete remission, which may last months or 
years (Filippi et al., 2018). Eventually, patients enter the secondary progressive phase, 
when permanent disability accumulates (SPMS). More rarely, disability accrues from 
the start (PPMS). 
 
Although there is no cure for MS, disease-modifying drugs (DMDs) can significantly 
reduce relapse rates and disease progression (Fogarty, Schmitz, Tubridy, Walsh, & 
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Barry, 2016). However, DMDs are only effective in the relapsing forms of MS, with the 
exception of Ocrelizumab (licenced for PPMS) and Siponimod (licenced for SPMS). 
People with MS face a difficult decision when it comes to weighing up the various costs 
and benefits of DMDs as the complex risk-benefit profiles are not always correctly 
interpreted and understood by people with MS (Reen, Silber, & Langdon, 2017a). 
Decision-making in these situations may be compromised by the fact that people with 
MS choose differently when making decisions under risk conditions (Farez, Crivelli, 
Leiguarda, & Correale, 2014). Furthermore, there is often a difference between patients 
and health professionals in terms of risk acceptance and risk perception (Heesen et al., 
2010).  
 
It is important that patients are able to understand the complex risk and benefit 
information surrounding DMDs, to inform their decisions about treatment. Shared 
decision-making as part of a patient-centred approach has been advocated (Barry & 
Edgman-Levitan, 2012); patient understanding is a prerequisite for successful medical 
decision-making. Of particular importance is the evidence that shared-decision making 
is associated with better DMD adherence rates in MS; this is critical as the efficacy of 
DMDs depends on high levels of adherence (Ben-Zacharia et al., 2018).  
 
The Decisional Conflict Scale (DCS) is a commonly used self-report measure to assess 
personal values (O’Connor, 1995). The scale assesses patient uncertainty in decision-
making and asks questions related to how informed, supported and clear people feel 
about the decision they are making. Patients report improved satisfaction and less 
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uncertainty about the course of action to take when partaking in shared decision-making 
(Shay & Lafata, 2015). 
 
Identifying how to design effective communication of the evidence, regarding the 
benefits, risks and uncertainty of treatments, in a way that is clear, accessible and usable 
is a key priority for research. This is highlighted by various government notes (“PN 
500”, 2017), reports (The Academy of Medical Sciences, 2017) and international 
initiatives (Rieckmann et al., 2018).  A recent qualitative study highlights the 
importance of taking into account the contextual factors (clinical, social and 
psychological) of patients’ everyday lives when making decisions regarding initiating 
DMDs (Eskyte et al., 2019). 
 
3.2.1. MS symptoms 
 
People with MS experience a range of symptoms including fatigue, anxiety, depression 
and cognitive impairments (Thompson et al., 2018). Cognitive deficits, demonstrated at 
all stages of the disease, are likely to impact on patients’ general understanding and 
ability to recall important information, which could pose a challenge when deciding on 
a course of treatment (Reen, Silber, & Langdon, 2017a).  
 
3.2.2. Treatment in MS 
 
People with MS are required to make important decisions about DMDs. These drugs 
can help with the delay of disease progression, but they are associated with complex 
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risk-benefit profiles. The DMDs available for the treatment of RRMS vary in efficacy, 
mode of delivery and adverse event profile (De Angelis, John, & Brownlee, 2018). The 
breadth of treatments poses challenges in selecting the right treatment for the right 
patient at the right time (Thompson et al., 2018).  
 
Recent research has explored the differences in the way that health care professionals 
(HCPs) and people with MS see their needs (Rieckmann et al., 2018). Of particular 
relevance is the topic of burden of treatment in MS, in which three main areas were 
identified: risk versus benefit of MS therapies; treatment decisions; and compliance, 
adherence and monitoring. The review highlighted that there is often a difference 
between patients and HCPs in terms of risk tolerance. Specifically, people with MS 
thought that HCPs focus on negative rather than positive aspects of treatment. HCPs 
reported that they were concerned about the high level of risk patients are willing to 
take in relation to treatment benefits. The authors stressed the need for the development 
of patient-centred educational resources that can be used during consultations to 
enhance disease understanding and improve communication between patients and HCP.  
 
3.2.3. Interventions to support understanding  
 
15 interventions designed to improve MS patients’ understanding of the complex risk-
benefit profiles of DMDs were reviewed (Reen, Silber, & Langdon, 2017c). Overall 
understanding of treatment information and risks generally improved after 
interventions. Improvements in understanding the benefits of treatments were less clear; 
patients tended to overestimate treatment benefits.  Other factors likely to influence 
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patient understanding of DMDs were not fully investigated in the interventions included 
in the review. For example, only one intervention examined cognitive impairment. 
There was no definitive effect of interventions on DMD decision-making and no one 
intervention was raised as particularly effective. This review highlighted the need for a 
standardised evidence-based tool to communicate the risk and benefits of treatments in 
a way that improves their understanding, whilst taking into account all patient abilities, 
such a cognitive impairment. Furthermore, a recent review reports uncertainty in 
relation to the effectiveness of interventions for increasing the use of shared decision-
making due to a lack of evidence in the area (Legare et al., 2018). 
 
In light of this, researchers conducted a series of experiments in order to investigate the 
optimal methods of communicating treatment information to patients with MS (Reen et 
al., 2018). It was found that MS patients presented with treatment information in 
frequencies better understood information compared to information presented in 
percentages or verbal descriptions. They also found that presenting information in bar 
charts or line graphs was able to improve MS patients’ understanding in comparison to 
pictograms or pie charts. Based on the results of these studies, the authors developed a 
protocol; the Benefit and Risk Information for Medication in Multiple Sclerosis 
(BRIMMS), in order to improve patients’ understanding and certainty about treatment 
(Reen et al., 2017b).  
 
The researchers aimed to evaluate the effect of BRIMMS on patients’ understanding 
and confidence in treatment decisions, compared to standard presentation of treatment 
information used in the UK. A randomised controlled trial was conducted with 24 
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patients who had a diagnosis of RRMS. Patients were presented with a hypothetical 
disease (with similar progressive characteristics to MS) and two hypothetical treatments 
for this disease. The treatment risk-benefit profiles were based on DMD clinical trials in 
order to be reflective of real life clinical decisions. Risk benefits were presented for one, 
two and five years of taking the treatment. Each treatment had one minor risk, one 
adverse risk and one benefit. All patients experienced the four methods of presentation 
in a random order: BRIMMS protocol (spoken, spoken-written) and standard 
presentation (spoken, spoken-written). Understanding and decisional confidence were 
recorded after each condition. Fatigue, depression and anxiety, numerical reasoning, 
pre-morbid IQ and cognitive abilities were also assessed.  
 
Treatment understanding was significantly affected by conditions: BRIMMS spoken-
written produced the best understanding overall. Confidence in treatment decisions was 
also significantly affected by conditions. Decisional confidence was greater for 
BRIMMS spoken-written compared to standard. Cognitive factors, pre-morbid IQ, 
anxiety and fatigue were not related to understanding in the BRIMMS, but had negative 
influences for standard presentation. Depression did influence understanding on the 
BRIMMS. This study demonstrated that the BRIMMS protocol offered an effective, 
evidence-based format for presenting MS medication information. The preliminary 
experiments looking at different types of format presentations, found that 
neuropsychological status did influence understanding scores (Reen. Silber, & Langdon, 
2018). In the randomised control trial, by chance, there was little neuropsychological 
impairment within the sample which may account for the lack of association between 
neuropsychological scores and understanding scores. Consequently, there is a need for 
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this to be repeated.  
 
3.2.4. MS and risk attitude, perception and propensity 
 
An individual’s risk attitude, risk perception and propensity are important factors that 
may influence the treatment decision-making process. Once the effect of risk attitude, 
perception and propensity on treatment understanding and decision certainty is known, 
characteristics of the patients could be determined in advance of the consultation during 
which the information is presented. The information could be amended to support the 
shared decision-making process. A recent systematic review looking at methods to 
investigate patient preferences for treatment identified the influence of risk perception 
and uncertainty on treatment decisions as neglected research topics (Webb et al., 2018). 
 
Risk attitude is a construct that describes an individual’s decision-making in terms of 
taking or avoiding risk when deciding how to proceed under conditions of uncertainty 
(Rosen, Tsai, & Downs, 2003). Risk attitude has primarily been studied by using 
gamble scenarios (Prosser, Kuntz, Bar-Or, & Weinstein, 2002). Authors state that 
individuals are said to be risk averse if they prefer a lower guaranteed outcome rather 
than the average value of a gamble. Risk seekers are those that prefer a gamble rather 
than a guaranteed outcome, with the same average value. Individuals are described as 
risk neutral if they are indifferent to a guaranteed outcome and a gamble with the same 
expected value (Prosser et al., 2002). 
 
Risk-taking behaviour may be influenced by more than risk attitude, it may also be the 
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result of an individual’s risk perception, which is the perceived likelihood of 
experiencing a negative event (Harrison, Young, Butow, Salkeld, & Solomon, 2005). 
Furthermore, existing research suggests that disease risk perceptions are critical in 
determining health behaviour (Ferrer & Klein, 2015). Decision-making may also be 
influenced by an individual’s risk propensity, which is defined as an individual’s current 
tendency to take or avoid risk, described as a trait that can change over time as a result 
of experience (Sitkin & Weingart, 1995). It is therefore likely that decision-making 
regarding treatments may reflect individual perception of risk, attitude towards risk and 
risk propensity (Glanz et al., 2016).  
 
Previous research has investigated risk attitude and risk perception in individuals with 
MS using risk attitude and risk perception rating scales and a standard gamble scenario 
(Glanz et al., 2016). Interestingly, MS patients were found to be risk neutral overall, but 
risk averse when issues were related to health and safety. Risk attitude has been found 
to be related to treatment choice in MS patients (Prosser et al., 2002). Specifically, the 
more risk-seeking a patient was, the more likely they were to choose ‘no treatment’ as 
an option compared to more risk averse patients. Subsequent researchers were interested 
in assessing the impact of MS on evaluating decision-making under explicit risk 
(Simioni et al., 2012). Compared to healthy controls, MS patients showed deficits on a 
task which probed the anticipated effects of decisions outcomes on future choices and 
MS patients had a greater risk aversion. Patients also differed from controls in the 
quality of their decision-making. This study highlighted that the quality of decision-
making under risk was modified by MS.  
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Furthermore, results from a recent systematic review looking at decision-making in MS, 
reported an overall alteration of decision making ability in MS patients compared to 
controls. Specifically, MS patients’ decision-making under risk was altered in 67% of 
tests analysed and decision-making under ambiguity was affected in 64% of 
measurements as measured by the Iowa Gambling Task (Neuhaus, Calabrese, & Annon, 
2018).  
 
3.2.5.The current study 
 
Further research is needed to confirm whether BRIMMS is superior to presenting 
information in a standard form (Reen et al., 2017b). The current study will examine 
whether anxiety, depression, fatigue and cognitive impairment relate to patients’ 
understanding scores on treatments and certainty in treatment decisions. It will also 
investigate whether BRIMMS is superior to standard presentation in improving 
patients’ understanding scores on treatment and increasing patient certainty in decisions. 
The current study aims to expand on previous research by investigating how self-
reported and objective risk attitude, risk perception and propensity to take risks relate to 
patient understanding scores and certainty in treatment decision. The research is 
justified given the lack of studies in this area and the fact that this information could be 
used to determine patient characteristics in advance of the consultation during which the 
information is to be presented. It would mean that the presentation of the information 
could be amended to support the shared decision making process between patient and 
healthcare professionals. 
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The current research will be conducted with patients who have RRMS. Patients will 
then receive hypothetical medication information via both the BRIMMS and standard 
presentation. In order to assess understanding, patients will be asked questions about the 
information they received and asked to choose between the two medications they were 
given. They will also be asked questions in relation to their confidence in that decision. 
Each patient will be given questionnaires and tasks in relation to mood, fatigue, memory 
as well as risk attitude, perception and propensity. 
 
3.2.6. Summary 
 
The literature supports the view that patient-centred educational resources can aid in the 
understanding and certainty of patients’ decisions regarding treatment. To understand 
this further, it is important to replicate previous findings (Reen et al., 2017b). The 
literature suggests that an individuals’ risk attitude, perception and propensity are likely 
to have an impact on decision-making. There are currently no studies investigating the 
effect of risk attitude, perception and propensity on decision-making whilst using an 
educational resource. Therefore, the proposed study would be the first study to 
investigate the relationship of risk attitude, perception and propensity to decision-
making whilst using a standardised protocol. This has clinical implications regarding 
management, understanding and treatment of individuals with MS. 
 
3.2.7. Research question and hypothesis 
 
3.2.7.1. Confirmatory 
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Does the BRIMMS improve patients’ understanding around treatment risks and benefits 
compared to standard consultation?  
 
Does the BRIMMS reduce patients’ conflict in their treatment decisions compared to 
standard consultation?  
 
3.2.7.2. Novel 
 
Is self-reported risk attitude, risk perception and propensity to take risks associated with 
patient understanding and certainty in treatment decisions?  
 
The hypotheses for this study were as follows: 
1) The BRIMMS protocol would improve patients’ understanding of treatment 
risks and benefits compared to standard consultation. 
2) The BRIMMS protocol would reduce patients’ conflict regarding treatment 
decisions compared to standard consultation. 
3) The BRIMMS would be rated more positively by patients than the standard 
consultation. 
4) Self-reported risk attitude (Glanz et al., 2016), perception (Glanz et al., 2016) 
and propensity to take risks (Bechara, Damasio, Damasio, & Anderson, 1994) 
will predict patient understanding. 
5) Self-reported risk attitude (Glanz et al., 2016), perception (Glanz et al., 2016) 
and propensity to take risks (Bechara et al., 1994) will predict patient certainty 
in treatment decisions. 
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3.3.Methodology 
 
3.3.1. Research Approval 
Following Proportionate Review, a favourable ethical opinion was received from the 
NHS Health Research Authority (See Appendix A & B). Permission for recruitment of 
MS participants was given by the Research and Development department at The Royal 
Free London (Royal Free NHS Foundation Trust; See Appendix C). The experiment 
also received ethical approval from the Psychology Department Ethics Committee at 
Royal Holloway, University of London. 
 
3.3.2. Design 
 
The study had a repeated-measures design comparing two formats of presentation of 
material. A neuropsychological test battery and questionnaire battery were administered 
to participants.  
 
3.3.3. Participants 
 
A total of 26 patients diagnosed RRMS were recruited. Patients were recruited from 
The Royal Free London Hospital, NHS Foundation Trust.  
 
3.3.3.1. Inclusion/Exclusion Criteria 
 
Inclusion 
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All participants: 
 were fluent in English. 
 were aged between 18 and 65 years. 
 had a diagnosis of RRMS by a Consultant Neurologist based on Thompson et 
al., (2018) criteria. 
 were able to give informed consent. 
 were able to meet the task demands of the experiment in terms of sensorimotor 
abilities. 
 
Exclusion 
Participants who had: 
 significant changes in medication or condition within the last four weeks. 
 a history of significant psychiatric disorders, substance or alcohol abuse. 
 a significant medical condition (other than MS), personal or social 
circumstances that were likely to impact on participating in the study. 
 significant visual, motor or hearing impairments that would have an impact on 
their engagement with the tests/protocol/questionnaires. 
 
3.3.4. Recruitment 
 
3.3.4.1. MS Participants Identification 
 
MS participants were recruited from The Royal Free NHS Foundation Trust. 
Participants were initially approached by the clinical teams and given a patient 
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information sheet (See Appendix D). Patients then contacted the researcher to express 
interest. Alternatively the researcher was present on clinic days and met with patients 
after they had seen the clinic team (if they had given permission for the researcher to 
approach them). A leaflet was also created for the purpose of recruitment (See 
Appendix E). Once contact had been made, a home visit was arranged to gain written 
consent (See Appendix F) and collect data. All participants were well known to the 
treatment team and home visits were therefore deemed an appropriate way to collect 
data. Participants were informed that they were free to withdraw at any time, without 
giving a reason and informed that this would not impact on their care. This information 
was provided on the patient information sheet and on the consent form. 
 
3.3.5. Lone Working 
 
The Royal Free NHS Trust Foundation Trust Lone Working Policy (August 2017) was 
adhered to with risk being assessed on a participant by participant basis and a buddy 
scheme was in place with the Research Nurse. 
 
3.3.6. Data Storage 
 
Participants were allocated an anonymised participant identification number. Study 
documentation was kept in a locked cabinet, in a locked room. Data was stored in an 
encrypted spread sheet. 
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3.3.7. Power Analysis  
 
A power analysis was conducted using data from Reen et al. (2017b), due to the 
similarity of the design. The effect sizes range from 0.4 to 0.8 on the validated DCS 
(O’Connor, 1993). Although the previous study found large effects on the DCS measure 
when comparing BRIMMS with standard consultations, a conservative medium effect 
size (0.5) on the DCS will be presumed for this study. It was estimated that for an alpha 
of 0.05 and power of 0.90, at least 46 MS patients would be required in accordance with 
procedures (Senn, 1999).  
 
3.3.8. Materials and Methods  
 
Two types of consultation were evaluated in the experiment: standard and BRIMMS. 
Patients received both conditions. To control for order effects on the BRIMMS and 
standard consultation, the conditions were counterbalanced; patients were assigned to 
one of four different orders of presentation (See Appendix G). Half of participants 
received the BRIMMS first, and half of participants received the standard first. The 
order of the two hypothetical treatments within each condition was also 
counterbalanced. The first participant received order one, the second participant 
received order two, the third participant received order three and so on. The cycle was 
then repeated, so that the fifth participant received order one, the sixth participant 
received order two and so on. 
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Throughout the experiment, patients were given information about one hypothetical 
disease. Hypothetical information was used in order to avoid discussions surrounding 
medical information without appropriate professional support. The disease was 
described as progressive and a list of symptoms were presented (See Appendix H). 
Patients were told that the hypothetical disease was progressive in nature and could vary 
between patients, in order to mimic the uncertain and progressive nature of MS. Patients 
were also told that they might not experience all of the symptoms of the hypothetical 
disease. 
 
Information was given to participants about two hypothetical treatments, this consisted 
of one benefit, two minor risks and one adverse risk for each treatment. All information 
was provided for outcomes associated with short-term (one and two-years) and long-
term (five years). All risks and benefits mimicked real-life DMD risk and benefit 
profiles as closely as possible. The disease and treatment names were those used in the 
previous experiment (Reen et al., 2017b). 
 
3.3.8.1. BRIMMS 
 
The experimental intervention given to patients was the BRIMMS protocol, which was 
developed by a previous researcher as a method to present treatment information (Reen 
et al., 2017b). Participants were provided with a hypothetical clinical trial scenario 
where the treatment benefits were stipulated for the intervention group (those taking the 
treatment) and a placebo group (those not taking any treatment).  
 
 104 
The BRIMMS was created by considering the results from various experiments, 
outlined as followed (Reen et al., 2018). All quantitative information was presented 
using frequencies. Frequencies were presented using the format, N-in-N*X ratio, in 
which the denominator was kept constant and the numerator was changed to represent 
the benefit or risk. In addition, information was presented using horizontal bar charts 
with numbers. Absolute terms were used when presenting the differences in treatment 
benefits between the intervention group and the control group. 
 
The BRIMMS protocol was provided to patients both verbally and written (See 
Appendix I). The decision to present BRIMMS simultaneously in both verbal and 
written form was based on findings from previous experiments which found that 
BRIMMS spoken-written produced the best understanding overall (Reen et al., 2017b). 
 
3.3.8.2. Standard consultation 
 
The patients received treatment risks and benefits in a standard consultation format as a 
control condition. The standard consultation was that used in previous work, which had 
been developed by speaking to MS nurses about how treatment risk and benefit 
information is presented to patients in consultations (Reen et al., 2017b). The standard 
consultation was presented to patients simultaneously in both aural and written form 
(See Appendix J). 
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3.3.8.3. Outcome measures and assessments to measure patient characteristics 
 
Patient understanding 
Understanding of treatment risks and benefits was assessed by asking 15 
comprehension questions regarding the side-effects, adverse risks and benefits of each 
hypothetical treatment (Appendix K). The comprehension questions measured objective 
knowledge of treatment risks and benefits. The questions were those previously 
developed by a previous researcher (Reen et al., 2017b; Hamstra et al., 2014; Hawley et 
al., 2008). Patients could score a maximum of 15 points for each treatment, as 15 
questions were asked for each treatment (6 questions for treatment benefits after one 
year, two-years and five-years, three questions each for the two minor risks after one 
year, two-years and five-years). Therefore, a total score of 30 was possible for each 
condition as there were two treatments per condition.  
 
Perceived understanding was assessed as part of three feedback questions measured on 
a 10-point likert scale, that were asked at the end of each condition. A score of 
0=negative rating and a score of 10=positive rating. The questions were ‘How well did 
you understand the treatment information given to you during this session?’, ‘How 
satisfied were you with the way treatment information was given to you during this 
session?’ and ‘How much did you prefer the treatment information given to you during 
this session?’. 
 
Decisional conflict  
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The Decisional Conflict Scale (O’Connor, 1995; See Appendix L) is a self-reported 
questionnaire that was used to assess patients’ decisional conflicts regarding their 
treatment options. After being presented with each set of treatments, patients were 
required to make a decision regarding treatment (i.e. choose of the two hypothetical 
treatments, choose neither or say that they were unsure). The option of not choosing a 
treatment is not present in the original DCS but this was added in order to mimic real 
clinical decisions in MS (Reen et al., 2017b).  
 
The DCS was given twice to each patient, once after the BRIMMS and once after the 
standard consultation. After patients made a treatment choice, they were asked to 
respond to the 16 questions, with three subscales measuring decisional uncertainty and 
cognitive and social variables thought to be important in the decision making process. A 
five-point Likert scale (ranging from 0=strongly agree to 4=strongly disagree) is used to 
score each item. Scores can be standardised to range from no decisional conflict (0) to 
extremely high decisional conflict (100). Decisional conflict scores of 25 or lower are 
associated with continuing with a decision, scores above 38 suggest a delay in decision 
making (O’Connor et al., 1998). The test-retest reliability coefficient has been 
demonstrated to be high at 0.81 (O’Connor, 1995) and internal consistency for total 
DCS score has been shown to be high (coefficients ranging from 0.78 to 0.92, 
O’Connor, 1995). The DCS is recommended as an outcome measure to assess the 
impact of decision in people with MS (Wilkie, Solari, & Nicholas, 2019). 
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Risk measures 
The study assessed risk by following the risk assessment methodology of a previous 
study (Glanz et al., 2016; See Appendix M). This consisted of the following measures, 
presented to the patient in one risk questionnaire: 
 
Risk attitude/Risk propensity 
1) Single-item measure of risk orientation (Maestas & Pollock, 2010). This measure 
asks patients to rate their overall comfort with taking risks from extremely comfortable 
to extremely uncomfortable. A score of 1 or 2 indicates a risk seeking attitude, a score 
of 3, 4 or 5 indicates a risk neutral attitude and a score of 6 or 7 indicates a risk adverse 
attitude. The test-retest reliability of the measure is .94 in a lab setting and .69 in an 
internet survey (Maestas & Pollock, 2010).  It has been validated against the 32 item 
‘everyday risk-tasking inventory’ and performs as well as the RPS scales and other 
gamble measures (Maestas & Pollock, 2010). 
 
2) Risk Propensity Scale (RPS; Meertens & Lion, 2008). This is seven-item self-report 
measure of an individual’s general tendency to take risks. It consists of 7 items that tap 
into different aspects of risk taking. Patients are asked to rate each item on a 9-point 
scale (ranging from 1, totally disagree to 9, totally agree), apart from the last item, 
which is rated on a scale from risk avoider (1) to risk seeker (9). Higher scores indicate 
higher risk seeking tendencies. The RPS has demonstrated good internal reliability and 
test-retest reliability coefficients (Cronbach’s alpha .80; Meertens & Lion, 2008).  
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3) A standard gambling scenario. This scenario asks patients to consider a new drug for 
MS which promises no new relapses or worsening of MS symptoms, but stipulates that 
it could cause death. Participants are asked to indicate the likelihood that they would 
take the new drug if the risk of death was 1:2, 1:10, 1:100, 1:1,000, 1:10,000 and 
1:100,000. 
 
Risk perception 
1) Patients are asked to estimate the likelihood of becoming wheelchair-bound over the 
short- (two years), medium- (five years) and long-term (10 years) on a five-point scale 
(ranging from extremely unlikely to extremely likely).  
 
2) Patients are asked to estimate the likelihood of minor and serious side effects 
associated with a range of medications commonly prescribed MS drugs. 
 
Decision-making under ambiguity 
Iowa Gambling Task (IGT; Bechara et al., 1994) is used to evaluate learning and 
decision making under ambiguous conditions where the risk is not explicitly explained 
to the patient and the ability to learn which options are more advantageous is required. 
Patients have to choose from four decks of cards in 100 trials and win or lose certain 
amounts of fictitious money. Two decks are disadvantageous in the long term; 
associated with immediate high gain but higher unpredictable future losses and two 
decks are advantageous in the long term because they provide low immediate gain but 
lower unpredictable future losses. As these rules are not explained to patients, they need 
to learn to choose from the more advantageous decks. Decision-making under 
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ambiguous conditions has been reported to be impacted in MS (Neuhaus et al., 2018). 
The Iowa Gambling Task was downloaded from The Psychology Experiment Building 
Language (PEBL) website (http://pebl.sourceforge.net). The Iowa Gambling Task is 
one of the most widely used tests in the PEBL battery (Mueller & Piper, 2014), used in 
many contexts and has been shown to be valid (Piper, Mueller, Talebzadeh, & Jung Ki, 
2016).  
 
Sample Benchmarking 
Some of the measures and questionnaires included in the study are done so for reasons 
of benchmarking the sample. That is, to ensure that the sample is typical of other 
published samples. 
 
Cognitive tests  
The Brief International Cognitive Assessment for MS (BICAMS; Langdon et al., 2012) 
was used as a screening tool to identify cognitive impairment in patients with MS. It 
includes the Symbol Digit Modalities Test (SDMT), the learning trials of the California 
Verbal Learning Test II (CVLT-II) and the learning trials of the Brief Visuospatial 
Memory Test Revised (BVMT-R). The BICAMS is considered the gold standard 
cognitive screen to be used for people with MS (Corfield & Langdon, 2018).  
 
SDMT (Smith, 1982; See Appendix N) is a test of Information Processing Speed. In this 
test symbols are paired with specific numbers in a key at the top of the record sheet. The 
record sheet contains symbols only, the number pairing is left blank. Participants are 
required to vocalise the numbers that correspond to the symbols as fast as possible. 
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There is an initial practice set of 10 items to ensure that participants understand what to 
do. A total score is calculated from the number of correct responses within 90 seconds. 
The oral element of the task ensures that fine motor skills are not a confounding 
variable. The test-retest reliability coefficient has been reported to be 0.97 (Benedict, 
2005) and it is highly sensitive to detecting cognitive impairment in MS (Lopez-
Gongora, Querol, & Escartin, 2015). 
 
The CVLT-II (Delis, Kramer, Kaplan, & Ober, 2000; See Appendix O) measures 
episodic verbal learning and memory. The CVLT-II is a list comprising of 16 words, of 
four different categories. The list is read out at a rate of one word per second and the 
participant is asked to respond with as many words as they can recall. The list is read 
five times over five trials, with a maximum score of 16 per trial. A total score over the 
five trials is calculated, with a maximum total score of 80.  It has been shown to be 
valid test of verbal memory in MS (Stegen et al., 2010). 
 
The BVMT-R (Benedict, 1997; See Appendix P) is a test of visual memory. Participants 
are presented with an array of 6 geometric figures for 10 seconds. After 10 seconds the 
stimulus sheet is removed and participants are given a blank piece of paper and asked to 
draw the shapes as accurately as they can and in the same position as they were on the 
stimulus sheet. This is repeated for 3 trials. One point is allocated for accurate drawing 
and one point for accurate placement (a total of 2 points per figure). Each trial has a 
potential score of 12, therefore a total maximum score is 36. The psychometric 
properties of the BVMT-R have been demonstrated to be good (Gaines, Gavett, Lynch, 
Bakshi, & Benedict, 2008).  
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The Wechsler Test of Adult Reading (WTAR; Wechsler, 2001; See Appendix Q) is a 
brief measure used to predict premorbid IQ. It consists of 50 irregular English words 
which participants are required to read aloud. Each correctly pronounced word is 
recorded. The raw score can be transformed to an age-adjusted standard score which is 
then used to predict IQ. WTAR scores have been found to be highly correlated with 
measures of verbal IQ (r = .75) and full scale IQ (r = .73) (Strauss, Sherman, & Spreen, 
2006). 
 
Questionnaires 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983; See 
Appendix R) was used to assess affective MS symptoms. The HADS is a widely used 
measure of emotional distress and has two subscales measuring anxiety and depression, 
each comprising of seven items. Each item has response options ranging from 0 (not at 
all) to 3 (very much), with higher scores suggesting higher symptom severity. The 
maximum score for each subscale is 21 points. Patients scoring above 11 points on a 
subscale are considered to have a clinical level of anxiety or depression. A score 
between 8 and 10 on a subscale indicates borderline anxiety or depression. The HADS 
has demonstrated good internal consistency (Honarmand & Feinstein, 2009). Previous 
research has highlighted its sensitivity to depression and anxiety in MS (Watson, Ford, 
Worthington, & Lincoln, 2014).  
 
The Fatigue Severity Scale (FSS; Krupp, LaRocca, Muir-Nash, & Steinberg, 1989; See 
Appendix S) is a nine-item self-report questionnaire originally developed for people 
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with MS.  It comprises of nine items scored on a seven-point likert scale (1=strongly 
disagree; 7=strongly agree) and takes between 2-5 minutes to administer. It asks 
patients to rate their psychological or physical fatigue in the past seven days. A mean 
score is calculated and people scoring 5 or higher are deemed to have severe fatigue. 
The FSS has shown to be valid measure (Amtmann et al., 2012), with high internal 
consistency and high test-retest reliability (Learmonth, Moti, Sandroff, & Cadavid, 
2013).  
 
Demographics 
Patient age, gender, ethnicity, level of education, employment status, years since MS 
diagnosis, EDSS and current DMD were collected on a questionnaire at the start of the 
experiment.  
 
3.3.9. Procedure  
The Consultant Neurologist or the Specialist MS Nurse at the hospital assessed patients 
for eligibility. If patients were interested they were given a information sheet and 
consent form, both approved by the NHS. Following providing consent, patients were 
seen at the hospital or at their home. The experiment took approximately one and a half 
hours to complete. Initially the researcher collected demographics and presented a 
visual acuity scale. 
 
Patients were then shown the hypothetical disease. The researcher read the hypothetical 
disease out to the patient and the patient was given a hardcopy to consult during the 
presentation not throughout the understanding questions. The researcher then referred to 
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the allocated participant number referring to the randomisation number which referred 
to the order in which the patient would receive the BRIMMS and standard, as well as 
the order in which the treatments would be presented. It was ensured that all treatment 
combinations were represented equally, controlling for variation. 
 
Patients were asked to imagine that they were at the early stages of the fictitious disease 
at which point only two treatments were offered (this was asked at the start of both the 
BRIMMS and the standard condition).  They were then informed that the purpose of the 
session was for them to decide whether they would take one of the treatments for the 
hypothetical disease. Patients were not told whether they were receiving the BRIMMS 
or the standard condition.  
 
Patients were asked comprehension questions after learning the risks and benefits of 
each treatment. Once patients had been presented with both treatments in any one 
condition, they were asked to make a decision on treatment (assessed using the DCS). 
Participants were then given three feedback questions, one of which assessed perceived 
understanding.   
Patients were then given the measures to assess risk, premorbid IQ, cognition, fatigue, 
anxiety and depression (Figure 5).  
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Risk questionnaire 
 
Iowa Gambling Task 
 
The Brief International Cognitive Assessment for MS 
 
The Wechsler Test of Adult Reading 
 
The Fatigue Severity Scale 
 
The Hospital Anxiety and Depression Scale 
 
Figure 5. Order of risk measures and benchmarking variables 
 
 
3.3.10. Statistical analysis 
 
All statistical analyses were conducted using IBM SPSS 21.0 (IBM Corp; Armonk, 
New York, USA). A within-subjects ANOVA assessed the impact of condition on 
patient understanding and confidence in decision making. Pearson product-moment 
correlations examined the relationship between understanding/certainty in treatment 
decisions and anxiety, depression, fatigue, and cognitive impairment. Pearson product-
moment correlations examined the relationship between self-reported risk attitude, risk 
perception and propensity to take risks and patients’ understanding and certainty in 
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treatment decision. Due to carrying out multiple corrections, a level of < .01 was 
accepted as significant in order to card against type 1 errors. In addition to an ANOVA, 
an ANCOVA was used to assess the impact of condition on patient understanding due 
to significant associations between fatigue, depression and anxiety and patient 
understanding. Therefore, fatigue, depression and anxiety were entered as covariates in 
this analysis. A cognitive composite score was created for each participant. The scores 
for the CVLT-II, SDMT and the BVMT-R for each participant were transformed into z-
scores and then added together in order to create the composite score. This composite 
score was entered as a covariate. People with MS can have difficulties in a range of 
cognitive domains. The general cognitive impairment score allows analysis with one 
statistical test utilising one cognitive summary variable (Goverover et al., 2016). To 
analyses each of the three cognitive scales would have increased the number of tests and 
reduced power. 
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3.4. Results 
 
3.4.1. Exploratory Data Analysis 
 
Due to constraints of time, patient recruitment was somewhat slower than expected (see 
Figure 6). A total of 26 patients were analysed in the study, with no missing data. The 
data was examined to determine if the assumption of normality was met, as required for 
the use of parametric tests. A cut off of ± 2.58 (p > .01) was considered for kurtosis and 
skew as recommended by Tabachnick & Fidell (2013). The distribution of the data was 
considered normal. When considering outliers, scores were checked to ensure that they 
were not 3SD ± mean. 
 
3.4.2. Demographic and Clinical Variables  
 
Participant demographics (see Appendix U) and clinical variables (see Appendix V) 
were in line with previously reports in the literature. Participants age was in line with 
previously reported studies (Bichuetti et al., 2018; Bsteh et al., 2017; Kopke et al., 
2017; Giordano et al., 2018). The ratio of male/female is consistent with published MS 
prevalence data (Mackenzie, Morant, Bloomfield, MacDonald, & O’Riordan, 2014). 
The mean IQ was average (103). In the general population, 50% of individuals have an 
IQ that falls between 90-109 (Wechsler, 2014). This suggests that participants in the 
current study are representative of the general MS population. 
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The means on the HADS are consistent with previously published means in the MS 
population (Pais-Riberio, Martins da Silva, Vilhena, Moreira, Santos, & Mendonca, 
2018). Average age at diagnosis, EDSS scores and FSS score were in line with previous 
reports in the literature (Rejak, Jackson, & Giovannoni, 2010; Bichuetti et al., 2018; 
Heesen et al., 2017; Kroencke, Lynch, & Denney, 2000).  
 
10 (39%) participants were impaired on the SDMT, 7 (27%) were impaired on the 
CVLT-II and 8 (31%) were impaired on the BVMT-R (see Appendix W). When 
comparing the sample means with published norms, the current sample is consistent 
with previous norms (Orchard, Giovannoni, & Langdon, 2013). 
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Figure 6. Recruitment pathway 
*(N is an estimation
Consultant Neurologist or 
Specialist MS Nurse assess patient 
for eligibility 
N=200* 
 
Patient asked if they would be 
interested in talking to the 
researcher about the study 
N=40 
Patient is either approached by 
researcher in clinic or given 
researchers contact details in order 
to discuss study and arrange a 
study visit 
N=26 
 
No further 
action 
Patient does not meet 
eligibility criteria 
Patient meets eligibility criteria 
End of research 
contact 
 
Patient not interested in 
taking part 
Patient interested in research study 
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3.4.3. Associations between clinical characteristics, cognition and outcome measures 
 
As expected confounding variables were significantly inter-correlated, consistent with 
previously published work (See Appendix T; Skerrett & Moss-Morris, 2006). 
 
A Pearson product-moment correlation was conducted to examine the relationship 
between each of fatigue, anxiety, depression, cognition and understanding score. There 
was a significant negative correlation between depression and BRIMMS understanding, 
that is, higher level of depression were associated with lower understanding scores on 
the BRIMMS (r(24) = -.57, p =.002). There was a significant negative correlation 
between anxiety and BRIMMS understanding, that is, higher levels of anxiety were 
associated with lower understanding scores on BRIMMS (r(24) = -.79, p < .001). There 
was a significant negative correlation between fatigue and BRIMMS understanding, that 
is, higher level of fatigue were associated with lower understanding scores on BRIMMS 
(r(24) = -.41, p = .039). There was no significant correlation between cognition and 
understanding (r(24) = .38, p = .054). 
 
A Pearson product-moment correlation was conducted to examine the relationship 
between each of fatigue, anxiety, depression, cognition and decisional conflict. There 
were no significant associations between either fatigue (r(24) = .12, p = .549), 
depression (r(24) = .15, p = .457), anxiety (r(24) = .01, p = .982), cognition (r(24) = -
.18, p = .372) and consultation as usual DCS score. There were no significant 
associations between fatigue (r(24) = .08, p = .682), depression (r(24)= .34 p = .086), 
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anxiety (r(24)= .15, p = .470), cognition (r(24) = .18, p = .376) and BRIMMS DCS 
score. 
 
3.4.4. The effect of BRIMMS protocol and standard consultation on patients’ 
understanding  
 
A repeated measures ANOVA was carried out on the data. Mean scores for patients 
understanding are presented below (Table 6). Higher mean scores indicate greater 
understanding of treatment information. The mean difference between conditions was 
24.23. Using the Greenhouse-Geisser correction, results showed that this difference was 
significant, F(1,25) = 3388.83, p < .001, 95% CI (23.372-25.088) ); an overall effect 
size of 0.99 (partial n2) showed that 99% of the variation in error scores can be 
accounted for by condition. Anxiety, depression and fatigue were co-varied together in 
the ANOVA. The effect of condition remains significant after co-varying anxiety, 
F(1,22) = 13.28, p = .001, but not depression, F(1, 22) = .44, p = .517) or fatigue, 
F(1,22) = .35, p = .558. 
 
3.4.5 The effect of BRIMMS protocol and standard consultation on patients’ decisional 
conflict  
 
A repeated measures ANOVA revealed that there was a significant effect of condition 
on patients’ decisional conflict, F(1,25) = 10.78, p = .003. Mean scores for patients’ 
decisional conflict are presented below (Table 7). Lower scores indicate reduced 
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decisional conflict. The BRIMMS protocol was associated with lower decisional 
conflict.  
 
3.4.6. The effect of BRIMMS protocol and standard consultation on patients’ feedback  
 
A repeated measures ANOVA revealed no significant effect of consultation on patient 
feedback, F(1,25) = .94, p = .339. Higher mean scores indicate more positive feedback 
(Table 8).  
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Table 6 
Mean scores for patient understanding across both conditions 
Condition Max score x̅  (SD) Confidence interval 
(95%) 
Minimum score Maximum score 
BRIMMS protocol 30 27.58  (1.67) 26.90-28.25 25 30 
Standard consultation 30 3.35 (1.29) 2.82-3.87 2 6 
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Table 7 
Mean scores for decisional conflict across both conditions 
Condition Max score x̅  (SD) Confidence interval 
(95%) 
Minimum score Maximum score 
BRIMMS protocol 100 24.21 (14.91) 18.19-30.24 0 58 
Standard protocol 100 38.28 (17.32) 31.28-45.27 6.3 83 
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Table 8 
Mean scores for patient feedback across both conditions 
Condition Max. total 
score 
x̅  (SD) 
 
Confidence interval (95%) Minimum score Maximum 
score 
BRIMMS  10 7.22 (2.07) 6.4-8.1 2.5 10 
Standard  10 6.55 (2.59) 5.5-7.6 1.7 10 
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3.4.7. Associations between risk measures and decisional conflict score and/or 
understanding  
 
On a single-item measure of risk orientation the mean score was equal to the middle of 
the scale, indicating a risk neutral attitude (M = 4; SD = 1.92; Table 9). Using the RPS, 
the mean (SD) risk propensity summary score was 3.70 (1.84), indicating an overall 
aversion to taking risks. On the IGT mean total score was 13.85 (SD = 31.76).  
 
Using a standard gamble scenario, individuals reported the likelihood of taking a new 
MS drug given the probability of a fatal side effect (See Table 10). 4% of participants 
indicated they were likely to take the drug if the risk of death was 1:2. The proportion 
increased to 27% if the risk of death was reduced to 1:1,000, and to 54% if the risk of 
death was 1:100,000. 23% of participants indicated that they were unlikely/extremely 
unlikely to take the drug even if the probability of a fatal side effect was 1:100,000. 
 
A Pearson product-moment correlation was conducted to examine the relationship 
between risk measures and decisional conflict and also understanding score. There were 
no significant associations between these variables. There were no significant 
associations between single-measure of risk orientation (r(24)= .04, p = 840), RPS 
(r(24)= -.01, p = .952), mean net score on Iowa gambling task (r(24)= -.01, p = .973) 
and BRIMMS DCS score. There were no significant associations between single-
measure of risk orientation (r(24)= .12, p = .545), RPS (r(24)= .16, p = .424), mean net 
score on Iowa gambling task (r(24)= -.00, p = .987) and BRIMMS Understanding score. 
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Table 9 
Descriptive statistics for risk measures 
 
 
 
 
 
Measure Maximum total 
score 
x̅  SD Minimum Maximum Confidence interval 
(95%) 
Single-measure 7 4.00 
 
1.92 1 7 3.2-4.8 
RPS 9 3.70 
 
1.84 1 7.1 3.0-4.4 
Mean net score - 13.85 
 
31.76 -40 72 1.0-26.7 
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Table 10 
Results from standard gamble scenario 
 Extremely unlikely 
N (%) 
Unlikely N (%) Neither likely 
nor unlikely N 
(%) 
Likely N (%) Extremely likely N 
(%) 
1 in 2 24 (92) - 1 (4) 1 (4) - 
1 in 10 22 (84) 2 (8) - 1 (4) 1 (4) 
1 in 100 20 (77) 3 (11) 1 (4) 1 (4) 1 (4) 
1 in 1,000 16 (61) 2 (8) 1 (4) 6 (23) 1 (4) 
1 in 10,000 8 (31) 6 (23) 2 (8) 5 (19) 5 (19) 
1 in 100,000 5 (19) 1 (4) 6 (23) 7 (27) 7 (27) 
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3.5. Discussion  
 
The current study aimed to confirm previous findings that BRIMMS is superior to 
standard consultation in improving patients’ understanding of treatment risks and 
benefits and reducing patients’ conflict regarding treatment decisions (Reen et al., 
2017b). Furthermore, it aimed to expand on previous research by investigating how 
self-reported and objective risk attitude, risk perception and propensity to take risks 
relates to patient understanding of treatment risks and benefits as well as certainty in 
treatment decisions. The influence of risk perception and uncertainty on treatment 
decisions have been identified as neglected research topics (Webb et al., 2018). 
Furthermore, risk perception is considered critical in determining health behaviour 
(Ferrer & Klein, 2015).  
  
3.5.1. Hypothesis 1: The BRIMMS protocol would improve patients’ understanding of 
treatment risks and benefits compared to standard consultation  
 
These results confirm previous findings that BRIMMS improved understanding 
compared to standard consultation (Reen et al., 2017b). Patients’ understanding of 
treatment risks and benefits was significantly better on the BRIMMS compared to 
standard consultation. However, it is important to note that anxiety, depression and 
fatigue were significantly associated with understanding scores on the BRIMMS. When 
these variables were co-varied in the ANOVA, the effect of condition on understanding 
was no longer significant, when depression and fatigue were accounted for. Therefore, 
the differences in understanding scores may be explained by either fatigue or 
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depression. However, depression and fatigue are part of the condition of MS and 
therefore these findings are not a reason to suggest that BRIMMS is unhelpful for 
patients with these symptoms (Thompson et al., 2018).  
 
3.5.2. Hypothesis 2: The BRIMMS protocol would reduce patients’ conflict regarding 
treatment decisions compared to standard consultation 
 
The second hypothesis was supported by the findings. The BRIMMS protocol was 
associated with significantly lower decisional conflict scores compared to standard 
consultation. This suggests that patients felt more informed, more confident in their 
treatment decision and clearer about their values. The results confirm previous findings 
(Reen et al., 2017b) and are in line with previous research that reports improved 
satisfaction and lower decisional conflict when patients partake in shared decision-
making (Shay & Lafata, 2015). The observed power reported by SPSS was 0.88, which 
suggests that the study was sufficiently powered to detect difference in the DCS despite 
the small sample size.  
 
3.5.3. Hypothesis 3: The BRIMMS would be rated more positively by patients than the 
standard consultation 
 
The hypothesis was not supported by the findings and therefore is not in line with 
previous research (Reen et al., 2017b). Whilst not actively seeking feedback, the 
researcher noted some spontaneous comments from patients, whilst they deliberated on 
what feedback score to give. The qualitative feedback outlined as follows may explain 
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the lack of difference in feedback scores. A few patients mentioned that they preferred 
the information when it was presented as percentages (as in the standard consultation 
condition). The comments regarding the graphs in the BRIMMS condition were 
variable, some patients liked them, whereas others thought that they were unnecessary. 
A couple of patients thought that the BRIMMS had too many numbers and preferred the 
more simple presentation of the standard consultation. Conversely, a few people 
mentioned finding the graphs and lay out of the BRIMMS slightly patronising. It was 
observed that patients giving this feedback were usually those who found it easier to 
understand numbers. This is important information that would need to be taken into 
account if the BRIMMS was rolled out to patients in the clinical setting. It would be 
useful to explain this concept in the standardised instructions for the BRIMMS, for 
example, explaining that some people might find the information easier to understand 
than others. 
 
3.5.4. Hypothesis 4 & 5: Self-reported risk attitude (single-measure of risk orientation), 
perception (RPS) and propensity to take risks (IGT) will predict patient understanding 
& Hypothesis 5: Self-reported risk attitude (single-measure of risk orientation), 
perception (RPS) and propensity to take risks (IGT) will predict patient decisional 
conflict scores 
 
Both hypotheses were not supported by the findings. There were no associations 
between risk measures and understanding/decisional conflict scores. This could be due 
to the small sample size of the study and therefore insufficient power in order to detect 
associations. A post-hoc power analysis for Pearson correlation was conducted in G* 
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Power to determine a sufficient sample size with an alpha of 0.05, a power of 0.80, and 
a large effect size (p = .5), the determined sample size was 29, where as the collected 
sample size was 26, reducing the power to .77. 
 
The results related to hypotheses four and five are interesting given that the literature 
suggests people with MS have difficulties making decisions under risk (Farez et al., 
2014) and are generally risk averse which may have implications for decision making 
regarding treatments.  
 
Despite the lack of associations between risk measures and understanding/decisional 
conflict scores, it is important to consider the context of the risk findings with previous 
research. Patients appeared to be risk neutral on the single measure of risk attitude 
which is in line with previous research (Glanz et al., 2016). The Risk Propensity Scale 
indicated that patients had an overall aversion to taking risks issues to health and safety, 
which reflects previous findings (Glanz et al., 2016). Mean total IGT score was in line 
with previous reports in the literature (Farez et al., 2014).  
 
In terms of risk perceptions, 31% of patients reported the risk of their MS worsening 
over the next 2 years was likely/extremely likely, and 46% and 57% at 5 and 10 years 
respectively. These estimates are higher than previous reports (Glanz et al., 2016). 
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3.5.5. Limitations 
 
The findings should be interpreted with caution given a number of limitations. Firstly, a 
medium effect size was used in the power calculation analysis, in hindsight it would 
have been more suitable to use a small effect size as a more conservative estimate. 
 
Due to the design of the study, (the fact that the same hypothetical disease and two 
treatments were used in both formats) it is possible that there may have been some 
interference. The study would have benefited from a more robust design with two 
different hypothetical diseases and four different hypothetical treatments. This would 
have ensured that every patient had learnt about two diseases, each with two different 
drugs, therefore reducing the possibility of interference from previous understanding or 
misunderstanding. It may also have been beneficial to administer the other measures 
between conditions in order to provide a break between conditions and reduce the 
likelihood of a carryover effect. However, conditions and order of treatments were 
counterbalanced in an effort to reduce systematic bias from order effects on BRIMMS 
protocol and standard consultation format presentations. 
 
The difference in length of presentation between the BRIMMS and the standard 
condition was not controlled for. This could have meant that the participants were more 
fatigued in the BRIMMS condition, and therefore could remember less information; 
however the longer length could also mean that they had longer to think about the 
information being presented to them and this extended exposure increased 
remembering. 
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The use of hypothetical disease and treatments raises the possibility that the findings 
may not apply to the understanding of real DMD risks and benefits, in that the 
information which was not personally relevant. This may have reduced patients 
emotional connection to the information and caused them to less engaged. However, the 
hypothetical disease and treatment profiles were aligned closely with the risks and 
benefits of real DMDs.  
 
Studies aiming to address these methodological difficulties have found that hypothetical 
diseases are an accepted methodology for exploring risk in MS patients (Bruce et al., 
2018). Other methodologies have included presenting patients with five attributes of a 
DMD: relapse prevention, disease progression prevention, side-effect risk, route of 
administration and frequency of administration (Sempere et al., 2017). A five-card 
game was used to assess preferences, where patients were then asked to rank the 
attributes from most preferred to least preferred. It was confirmed that these was a 
feasible way to assess preferences in MS patients. Alternatively, one study assessed 
attributes by asking a focus group to compile a list (Kremer, Evers, Jongen, & 
Hiligsmann, 2018). This information was then collated into a survey with several choice 
answers (from best to worst) and given to a larger patient group. A strength of this study 
in using a focus group means that patients’ perspectives were directly assessed, rather 
than relying on a set of attributions obtained from literature or through discussions with 
HCPs. It may be that a range of assessments would have strengthened the ecological 
validity of this study, had time allowed. 
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Side effect severity appears to impact decision-making regarding DMD; patients’ 
likelihood of taking a DMD systematically decreased as the efficacy decreased and side 
effect severity increased (Jarmalowicz et al., 2017). The results suggest that information 
on severe side-effects should be presented separately to mild and moderate side-effects. 
Although our design did not systemically vary severity of side effects, the way the 
information was presented was closer to the experience a patient would have in a real 
clinic decision-making scenario.  
 
Another limitation is the fact that the BRIMMS and standard consultation were not 
delivered by a MS health professional. Therefore, the presentation of the information 
was not identical to the experience as it would be in the clinic. It is important to 
consider how patients may interact differently if information is presented by a nurse or 
neurologist in a clinical setting, and they are able to ask questions. Furthermore, patients 
did not have any prior knowledge of the information presented, this means that they 
were unable to research or form their thoughts about it, which differs from what would 
happen in reality. Previous research has documented that people with MS use the 
internet as a means to search for information related to treatments (Lejbkowicz, 
Paperna, Stein, Dishon, & Miller, 2010). Furthermore, patients were asked to make a 
decision on the DCS immediately after seeing the treatment information, this is different 
to real clinical settings, where patients usually have more time to deliberate over and 
research their decision. 
 
One of the key factors associated with shared decision making is patient preference 
(route of administration, work environment, lifestyle; Eskyte et al, 2019; Ben-Zacharia 
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et al., 2018). Patient preferences may influence DMD selection and adherence. 
Discussions regarding patient preferences may help evaluate risk-benefit trade-offs 
associated with DMDs. Although the DCS touches on patient values, our study could 
have benefits from a more precise measure of patient preferences.  
 
We did not include carers in our experiment. It is recognised that in a real clinical 
context, carers are likely to be involved in treatment decisions. We acknowledge the 
importance of including both patients and their family members when developing 
disease information and education materials (Mazanderani, Hughes, Hardy, Sillence, & 
Powell, 2019). This is an important area to think about for future research with the 
BRIMMS. 
 
Another study looking at factors associated with MS patient preferences for DMDs 
found that monthly out-of-pocket cost was the attribute that was rated as having the 
most importance overall (Hincapie, Penm, & Burns, 2017). This suggests that our 
findings are not necessarily generalisable to other health care systems where patients 
must pay for all or part of their drug costs (which is likely to play a huge role in their 
treatment choices). Our MS participants were recruited from the NHS and do not have 
to pay for their DMDs. 
 
It is possible that the study has selection bias, in that the attitudes and competencies of 
those that agreed to take part in the study may have differed from those that did not take 
part, which raises the possibility that the results may not be representative. For example, 
patients taking part may have been very interested in drug information and have more 
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background information/personal research on internet than the average patient; or 
patients with little understanding might have been embarrassed or ashamed to take part 
and hence less likely to volunteer. Another possible bias is that of the experimenter, the 
researcher may have indirectly influenced how the information was presented given that 
the researcher was not blinded to the condition that the patient received. It is important 
to take into account that environmental factors may have acted as confounds due to 
participants being assessed in their own homes. Participants were also tested at different 
times of day, which may have influenced the results in terms of differing fatigue levels. 
Although it is important to note that the sample in the current study was found to be a 
typical sample in terms of disease and demographic variables and the expected inter-
correlations of confounding variables were found.  
 
Another limitation is that fact that personality was not assessed or taken into account. 
Research shows that certain personality types are associated with various negative 
outcomes in MS (Strober, 2017). Specifically, ‘Type D’ personality was associated with 
more reports of fatigue, pain, depression, anxiety and worse disease management and 
adherence. It is likely that personality could have had an impact on the outcome 
measures in the current study.  
 
3.5.6. Clinical Implications 
 
The findings suggest that patients have incomplete understanding when treatment is 
presented in a standard consultation and BRIMMS has the potential to improve 
understanding of risks and benefits of DMDs. Implementing the BRIMMS in practice 
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could improve shared decision making, ensuring that patients choose a DMD with risks 
and benefits that they understand and consider acceptable. This could have an impact on 
adherence of DMDs, which is critical for long-term management of MS (Ben-Zacharia 
et al., 2018). Taking into account a patient’s objective risk attitude, risk perception and 
propensity to take risks could be useful in determining patient characteristics in advance 
of the consultation during which the information is to be presented. It would mean that 
the presentation of the information could be amended to support the shared decision 
making process between patient and healthcare professionals. 
 
3.5.7. Future research 
 
Future research should aim to see if the finding that the BRIMMS improves 
understanding and confidence in decisions regarding treatment risks and benefits 
compared to standard consultation is replicable in a larger sample. The aim would be to 
validate the BRIMMS in a clinical setting. Future research would benefit from a more 
robust design, where each patient received two different hypothetical diseases with four 
different hypothetical treatments. 
 
Future research, using a larger sample should measure risk alongside the BRIMMS in 
order to increase statistical power in order to detect any significant correlations risk 
attitude, risk perception, propensity to take risks and patient understanding scores 
regarding treatments as well as certainty in treatment decisions. Should an effect be 
found, risk orientation could be taken into account prior to discussions about DMDs in 
order to improve shared decision-making. 
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3.5.8. Conclusions 
This study confirmed previous findings that the BRIMMS protocol is associated with 
better patient understanding of treatment risks and benefits and reduced decisional 
conflict, compared to standard consultation. However, differences in understanding 
scores may be explained by either fatigue or depression. It is recommended that the 
BRIMMS should be further evaluated and implemented in during consultation in a 
clinical setting. The study found no associations between risk measures and 
understanding or decisional conflict, this could be due to the study being slightly 
underpowered. Further research should measure risk alongside BRIMMS in a larger 
sample. 
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4. Integration, Impact and Dissemination 
 
4.1. Integration 
 
The aim of the thesis was to investigate MS patients’ perceptions about the risks of MS 
and how this relates to their understanding of treatment risks and benefits and 
confidence in making these decisions. The systematic review provided an overview of 
the existing literature in regards to risk in relation to patients with MS. The systematic 
review provided an opportunity to summarise the literature in relation to patient’s risk 
perception, risk attitude, risk tolerance/risk acceptance and risk knowledge. This 
provided the conceptual background for the empirical study, and was therefore critical 
in the integration of the two pieces.  
 
The systematic review demonstrated that people with MS report uncertainty regarding 
the risks associated with DMDs. MS patients perceive the general risk to be higher than 
the risk they attribute to themselves. It was highlighted that elements of risk are related 
to treatment choice, for example, more risk seeking people were more likely to choose 
no treatment. Based on the findings of the systematic review it seemed necessary to take 
risk attitude, risk perception and propensity to take risks into account, in order to 
explore if there were any associations with understanding of treatment risks and benefits 
or certainty in treatment decision-making.  
 
It is important to note that the majority of studies included in the systematic review did 
not measure cognition or mood, which are variables that could influence risk perception 
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and acceptance. It was vital to include measures of anxiety, depression, verbal memory, 
visual memory and processing speed in the empirical study in order to explore any 
associations with risk.  
 
In addition to the risk measures, the empirical study aimed to replicate previous findings 
that the BRIMMS protocol improved patient understanding of DMD risks and benefits. 
This enabled a novel exploration of risk in MS, whilst aiming to confirm previous 
findings. The integration of the thesis is in line with policies and research that highlights 
the need for shared-decision making and solutions to enhance patient-physician 
communication, whilst providing patients with more autonomy in the management of 
their disease. It reflects the need to take into account patient preferences and 
characteristics prior to discussing DMDs in order to tailor communication effectively. 
 
4.2. Methodological difficulties 
 
4.2.1. Recruitment 
 
Due to a number of reasons, recruitment was slower than expected, resulting in a final 
sample size of 26 patients. Despite there being an average of 20 patients per clinic, not 
all of them had a diagnosis of RRMS, or met the inclusion criteria for the study. It was 
often the case that those who were suitable and approached by the research nurse, did 
not provide consent to take part. This may have been partly due to the volume of 
patients in the clinic and the time available for the research nurse to explain the study. 
There was also a period that the research nurse involved in recruitment for the research 
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was absent, which may have impacted on the speed of recruitment. Furthermore, a few 
patients agreed to take part in the study and subsequently cancelled due to symptoms of 
MS, for example relapses or severe fatigue.  
 
I responded to the recruitment difficulties by increasing my flexibility in terms of time 
of day and days of the week for patient visits. I also offered to see patients in their own 
homes. I made it a priority to contact patients that had shown an interest in the study, 
once they had provided consent for me to do so. Furthermore, I increased the number of 
clinics that I attended in an attempt to recruit more participants. My presence on the day 
of clinics enabled me to explain the study to patients and resulted in an increase in 
patient numbers. The research nurse was very helpful and ensured that she identified 
possible eligible patients prior to the clinic. This meant that she did not miss the 
opportunity to approach patients about the study. 
 
4.2.2 Response to risk measures 
 
Given the lack of associations between risk measures and understanding, I reflected on 
patients’ responses to the risk measures. It is important to consider that some people 
appeared to get bored whilst completing the Iowa gambling task, often asking how 
much longer they had left on the task. I wondered whether this led patients to select the 
same deck (rather than changing decks according to their risk propensity) in the hope 
that the task would finish earlier or due to the fact that they were no longer engaged in 
the task. It is therefore possible that the validity of this task within this study could be 
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questioned. Perhaps the length of the task could have been explained in more detail, in 
order to set the time expectations for the patient.  
 
The single-item measure of risk asked patients to rate their overall comfort with taking 
risks from extremely comfortable to extremely uncomfortable. A score of 1 or 2 
indicates a risk seeking attitude, a score of 3, 4 or 5 indicates a risk neutral attitude and 
a score of 6 or 7 indicates a risk adverse attitude. I wondered whether it might be hard 
for people to think about risk in general. This may have led to people choosing the 
‘neither risk seeking nor risk adverse’ option. However, this is unlikely given that this 
finding is reflective of previous research findings (Glanz et al., 2016). 
 
In terms of general reaction to risk measures, a patient made commented that he feels 
that his risk attitude changes according to how he is feeling about his MS. This made 
me reflect on how risk as a concept is potentially likely to change rather than be 
something that is static. Many patients explained that the current risk that they were 
willing to take was dependent on their age. Some people said that being older meant 
that they would be willing to accept higher risks, than they would have done when they 
were younger; they mentioned ‘I’ve got less to lose’. A couple of female patients 
explained that although they would technically want to accept higher risks they would 
not be willing to accept the risk due to the fact that their children were young and they 
would not want to risk not seeing the grow up. This made me think about how risk may 
be specific to stage in life or stage of disease. This made me consider the potential for 
future research to look at risk and understanding but with a follow-up period, so that 
risk and impact on DMD decision-making could be assessed at these different stages.  
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It is relevant to mention a research study, which aimed to explore the main factors 
affecting patients’ preferences regarding MS treatment (Lee Mortensen & Rasmussen, 
2017). Results demonstrated that although expected efficacy of DMDs was important to 
patients, this was modified by current well-being and Quality of Life related factors 
such as maintaining a positive self-image and a meaningful role that might be 
compromised by significant treatment burden. Authors link these findings to the Health 
Belief Model. Patients’ treatment preferences involved balancing up their present and 
future Quality of Life in terms of the anticipated gains and losses. The Health Belief 
Model stipulates that personal perceptions about the perceived susceptibility and 
seriousness of the disease (including its impact on Quality of Life) and perceived threat 
as well as perceived benefits and barriers of a behavior, determine health behavior. It is 
important to say that these four main constructs are modified by variables such as 
cultural, education, past experience, motivation (Glanz et al., 2016). The importance 
that patients place on their current Quality of Life and role compared to long-term gains 
needs to be considered in decision-making. Of particular importance here is the finding 
that patients’ DMD preference is in fact linked to age and disease progression and that 
parenthood may impact on the acceptability of risks and side effects (Wilson et al., 
2015).  
 
4.2.3. Defining structure for the systematic review 
 
Supervision was vital in guiding the process of deciding on a succinct structure for the 
systematic review. It consisted of a process of deciding how to arrange the different 
concepts of risk. Whilst analysing the papers for the review I noticed that there was 
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quite a lot of overlap between the different concepts of risk that researchers discuss. I 
assume this is a reflection of the findings of the systematic review, in the sense that 
there is no unified way to assess risk or define risk in relation to MS. My supervisor 
recommended a book for me on completing a literature review and ‘releasing the 
research imagination’ to read; this helped me to organise my ideas and present it in a 
way to guide the audience through the review (Hart, 2018). 
 
4.2.4. Lack of patient preference measures 
 
Recent research has identified that a key factor associated with shared decision-making 
is patient preferences. This includes route of administration, work environment and 
lifestyle (Ben-Zacharia et al., 2018). Patient preferences may influence DMD selection 
and adherence. Discussions regarding patient preferences may help patients to evaluate 
risk-benefit trade-offs associated with DMDS. In hindsight, it would have been useful to 
include a measure of patient preferences in our study. Patients often mentioned that 
irrespective of the risks and benefits of the DMD, their treatment decision was based on 
route of administration (e.g. tablet, infusion or injection), treatment schedule and how 
the DMD would fit into their lifestyle. This highlighted the need to consider the 
decision process in the context of the patient’s life and the vital need to understand what 
motivates a person in their treatment decision-making. This is reflective of recent 
research, which highlights the importance of taking into account the contextual factors 
(clinical, social and psychological) of patients’ everyday lives when making decisions 
regarding initiating DMDs (Eskyte et al., 2019). Overall, involving MS patients in the 
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decision-making process is crucial for selecting the treatment that best suits the patients’ 
objectives, preferences and lifestyles (Colligan, Metzlr, & Tiryaki, 2017). 
 
4.2.5. Non-MS health professional 
 
It is important to consider how patients may interact differently if the information was 
presented by a nurse or a neurologist in a clinical setting. The BRIMMS and standard 
consultation were delivered by a non-medical professional. It is likely that they would 
be able to answer specific questions that patients may have which would aid the 
decision making process. Whilst writing this section I considered the potential need to 
take into account cognitive biases or personality traits of the researcher/physician that 
administered the BRIMMS. A systematic review revealed how these biases or traits can 
affect clinical reasoning processes, which has implications for the management and 
treatment of medical conditions (Saposnik, Redelmeier, Ruff, & Tobler, 2016). 
 
4.3. Service User Involvement 
 
Service users were involved in the set-up of the study. Whilst I was writing my 
proposal, I outlined the design of the study and asked service users their perspectives 
about the concept of including risk. The feedback was very promising; service users felt 
that it was vital to take someone’s risk characteristics into account in order to tailor the 
shared decision-making process for that person. In terms of writing a lay summary of 
the results, I will be asking a service user to read the summary before I send it to 
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patients who have requested it. This will ensure that the results are clear and relevant to 
patients with MS. 
 
4.4. Impact 
 
The patients within this study are representative of the MS population in terms of 
gender, age, premorbid IQ and other clinical variables. This suggests that the results can 
be generalised to the MS population as a whole. The beneficiaries of this research 
include MS patients, professionals working clinically with MS patients, those 
conducting academic research, as well as policy-makers and commissioners who are 
responsible for developing best practice around MS disease management.  
 
I will discuss the areas in which I think the BRIMMS could have an impact clinically. 
There is scope for the communication between patients and HCPs to be improved. Risk 
knowledge is generally poor for MS patients (Giordano et al., 2018); patients generally 
underestimate DMD risks and overestimate DMD benefits (Reen, Silber, & Langdon, 
2017a). A systematic review of qualitative and quantitative research, to understand the 
experiences of HCP and patient interactions in MS, highlighted that some patients felt 
they had a lack of choice and felt powerless in regard to their treatment and care 
(Soundy, Roskell, Adams, Elder, & Dawes, 2016). One study found that about half of 
patients believed that they were not completely involved in choosing a therapy 
(Lorefice et al., 2013). Research demonstrates that patients would like more 
involvement in decisions (Yeandle, Rieckmann, Giovannoni, Alexandri, & Langdon, 
2018).  
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BRIMMS has the potential to increase patients’ understanding of treatment risks and 
benefits. It would provide the opportunity for patients to be more involved in the 
decisions about their care. This is critical as increased patient involvement in disease 
management is likely to improve patient commitment to therapy. More patient 
involvement in decision-making is associated with improved outcomes, reduced 
healthcare utilisation and improved service quality. This could be measured through 
adherence, direct healthcare costs and HCP-patient relationship satisfaction. 
The results offer important contributions to the clinical psychology literature and can be 
used to inform best practice regarding shared decision-making for the MS population. It 
is hoped that the study will lead to further research and implementation of BRIMMS 
within a clinical setting. For MS patients this has the potential to increase their 
understanding of DMD risks and benefits and make them feel more comfortable and 
confident in their treatment decision-making. If patients feel more comfortable with 
their decision and understand the risks and benefits, this is likely to lead to better drug 
adherence, which could lead to maintaining function for longer (Ben Zacharia et al., 
2018). In terms of impact from the risk element of the empirical study, the lack of 
relation of DMD understanding to patient risk profile, provides no support for risk 
screening prior to presenting information in the clinic. Although, it must be noted that it 
is a small sample size and possibly underpowered. 
 
The results provide professionals working with people with MS a tool that has the 
potential to aid in the shared decision making process. The impact for academic 
research is the hope that the study inspires academic researchers to replicate the study 
with a larger sample. In terms of the impact on policy makers and commissioners, it 
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may be beneficial to think about implementing the BRIMMS in practice in order to 
improve long-term outcomes. The study is relevant for public health policies; despite 
MS being a common neurological disorder, with effective DMDs, treatment adherence 
remains low. The BRIMMS has the potential to have an effect on treatment adherence. 
The findings compliment the research completed by the MS in the 21
st
 Century Steering 
group, which is committed to advancing shared-decision making. The BRIMMS has the 
potential to enhance the quality of life of people with MS, in terms of reducing relapses. 
 
It is important to consider the barriers that may influence the impact of this thesis. Some 
may argue that it would take longer to use the BRIMMS to communicate treatment 
risks and benefits than current practices that are in place. Future research could consider 
presenting BRIMMS on an iPad, this may increase the ease at which it could be used. In 
terms of affordability, the BRIMMS may help with adherence rates and in turn reduce 
relapse rates, which has a knock on effect for reduced utilisation of health resources. 
When considering how these benefits might be evidenced, the DSC could be used to 
measure patient satisfaction and decisional conflict. Perhaps there is a need for more 
studies examining the cost-effectiveness of decisional aids in terms of their effect on 
adherence rather than solely understanding. 
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4.5. Dissemination 
 
4.5.1. Presentations 
 
The preliminary results of the empirical study were presented in May 2019 at the Royal 
Holloway University of London third year Clinical Psychology Trainee presentation 
day. Attendees included clinical staff and Trainee Clinical Psychologists. The benefit of 
presenting to an academic audience allows the possibility that they may take forward 
the findings into their future projects. During discussions about my research, I was able 
to advise a fellow Trainee Clinical Psychologist in regards to the length of testing 
battery and recruitment strategy.  
 
There is the potential to present the results at a patient support group meeting. I am 
aware that establishing a network with service users increases the impact that research 
can have. I appreciate and acknowledge the active role that service users have in making 
the impact of research happen. A patient who participated in the research independently 
set up a patient support group and presents on radio shows about her experience of MS. 
This attitude and enthusiasm would be invaluable in terms of generating impact from 
research. 
 
4.5.2. Publications 
 
Both the empirical study and the systematic review will be prepared for publication in 
academic journal. The systematic review will be submitted to the Multiple Sclerosis and 
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Related Disorders (MSARD). The MSARD was selected as it is an international journal 
and aims to enhance the practice of academics involved in the care of people with MS. 
It has an impact factor of 3.2. A shorter version of the empirical study will be submitted 
to Multiple Sclerosis Journal (MSJ) for review, this is a highly respected journal with an 
impact factor of 5.3. A brief summary of the empirical study will also be sent to 
participants that requested a summary. This is in line with Good Practice Guidance from 
the Health Research Authority (“Good Clinical Practice”, 2018). 
 
4.6. Personal reflections 
 
I found completing this research a very thought-provoking and exciting opportunity. I 
have always been interested in neuropsychology and was extremely keen to complete a 
project within the area. I was inspired by the fact that the results of the study would be 
clinically relevant. In deciding upon a thesis, it was important for me to pick a project in 
an area that I feel passionate about.  
 
Furthermore, despite previously working with patients with a number of neurological 
conditions, I had not worked with people with Multiple Sclerosis. I was keen to 
complete my research with a new patient population. Working with MS patients whilst 
undertaking the research has further confirmed that I want to work in the area of 
neuropsychology as a qualified Clinical Psychologist.  
 
During this project, I attended a pop-up event in London, organised by the charity, 
Shift.MS. The event was a private viewing of a short film on the invisible symptoms of 
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MS. MS is most often known for the effect that it has on mobility. However, it is also 
associated with symptoms that are less well known, sometimes referred to as invisible 
symptoms. They include, but are not limited to, fatigue, depression, anxiety, dizziness, 
cognitive problems, and pain. These symptoms can be incredibly frustrating and can 
have a severe effect on Quality of life and daily functioning, such as managing at work, 
keeping up with conversations and managing activities of daily living.  
 
During the film, the symptoms are illustrated using doppelgangers and dance. My initial 
reaction to the short film was one of shock as the portrayal of some of the characters 
was fairly frightening. The film highlighted to me the fact that so often these hidden 
symptoms are under acknowledged. This knowledge was invaluable when completing 
my research study. It was helpful to think about how I would engage with patients with 
MS in the clinic or at home. One of the things that struck me was the importance of the 
film not only for the understanding for those without MS but for those with MS and the 
validation that it is perfectly normal to experience these hidden symptoms. Furthermore, 
this event was a useful opportunity for my supervisor to speak to her colleagues about 
the project that we were conducting.  
 
Whilst conducting the research, I started my third year clinical placement in a neuro-
rehabilitation setting. People with MS are faced with such uncertainties about the future, 
in terms of their symptoms, treatment and side effects of treatments. MS can impact on 
achieving life goals, job, income, relationships, social life and other daily living 
activities. Unsurprisingly, MS poses many psychological challenges in regarding to 
adjustment to MS as a diagnosis or the symptoms of the disease. I saw a few patients for 
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therapy for adjustment to MS work whilst I was on placement. This consisted of using 
the Cognitive Behavioural Therapy manual for adjustment to early stages of MS. This 
was a result of the randomised control Supportive Adjustment to MS trial (Moss-Morris 
et al., 2013). Interestingly ‘early stage MS’ refers to within 10 years of diagnosis. This 
was reflected in my work, as I saw people at with a range of years since diagnosis. 
People often experienced distress years after a diagnosis, when their MS had progressed 
and was stopping them from doing the things they used to be able to do. 
 
Whilst completing my research project alongside my placement, I was struck by the 
lack of psychological support that people had received in relation to their MS. I spoke to 
the research nurse about this and she explained that there is a lack of neuro-
rehabilitation services in the geographical areas that the patients live.  The nurse refers 
them to Improving Access to Psychological Therapies, or suggests that they self-refer. I 
wondered how adjustment, and the way that a person manages their diagnosis of MS or 
the disease in general, impacts on some of the risk measures. For example when asked 
the risk question about likelihood of disease progression, a few people explained that 
this is something they avoid thinking or speaking about. I wondered whether this may 
account for 38%, 27% and 35% selecting the ‘neither likely nor unlikely’ option for 2, 5 
and 10 years, respectively. By selecting this option, patients are not stipulating either 
way. This is a concept that I feel is related to the illness representation theory, which 
emphasises the need to look at everyday beliefs and coping strategies for illness to 
understand treatment choices (Leventhal et al., 1997). 
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Whilst on my final placement, in a paediatric setting, I was co-supervising an Assistant 
Psychologist. She was completing a systematic review as part of her placement year for 
her university degree. Discussing her systematic review made me reflect on my own 
review. It also made me aware how much my self-reflexivity skills have developed 
since I started training. 
 
Despite the drive for shared decision-making, and moving away from the paternalistic 
model (assuming a passive role for the patient) where the physician decides what DMD 
the patient should be on and expects the client to be compliant, many of the patients that 
I met said that they ‘just go with the DMD that the neurologist suggests’. Although it 
was not within the scope of the current study to explore this further, it made me think 
about the importance of how the medical professional explains the shared decision-
making process. Highlighting the likelihood of better adherence with increased 
understanding and the need for people to be happy with their choice and accepting with 
the specific risks and benefits.  
 
It seems appropriate to finish with my reflections in relation to a paper written by a 
member of the MS in 21
st
 Steering group and MS health professionals, about patient 
involvement in treatment decisions. I feel that the BRIMMS is a tool that is in line with 
the Steering groups’ goal to develop solutions to enhance patient-physician 
communication, whilst providing patients with more autonomy in the management of 
their disease.  
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Appendix D 
Participant Information Sheet 
 
 
 
 
 
 
 
 
 
 
PATIENT INFORMATION SHEET 
   
Effect of risk propensity on understanding and decision-making regarding 
disease-modifying drugs in Multiple Sclerosis 
 
 
We would like to invite you to take part in our research study. This research study is 
being conducted as part of a DClinPsy project at Royal Holloway, University of 
London. Joining the study is entirely up to you, before you decide whether to take part 
it is important that you understand why the research is being done and what it would 
involve for you. Please take time to read this information, and discuss it with others if 
you wish. One of our team will go through the information sheet with you, if there is 
anything that is not clear, or if you would like more information, please ask us. 
 
 
What is the purpose of the study? 
 
People with Multiple Sclerosis are faced with complicated information about the 
risks and benefits of disease-modifying medications. Recently, a researcher 
developed a novel way to present treatment risks and benefits of disease 
modifying drugs to patients with MS. The current study will compare the novel 
way of presenting information with usual presentation in order to find out 
whether one method helps improve understanding and confidence in treatment 
decision making more than another.  Furthermore, previous research has found 
that people with MS find decisions involving risk hard to make. Therefore, this 
study will investigate whether risk attitude and risk perception are related to 
understanding and certainty in treatment decision-making.  
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The aim of this study is to carry out a comparison of two methods of giving 
information with the hope of improving patients’ decision making about 
treatments.  
 
 
Why have I been invited? 
 
You have been given this information because your clinical team think that the 
study might be suitable for you. 
 
We are inviting 48 people to take part in the study. Clinical teams will refer people 
with MS to our research team. We then meet with each person to make sure that 
the research is appropriate for them and answer questions they may have. Each 
person who takes part will have a diagnosis of relapsing-remitting Multiple 
Sclerosis and be currently taking disease-modifying drugs. 
 
 
Do I have to take part? 
 
No, it is up to you whether or not you take part. If you do decide to take part, it will 
not affect the care you receive in any way. You can withdraw at any time, without 
giving a reason.  
 
 
What will happen if I decide to take part? 
 
You will meet with the researcher from the team to complete the study.  
 
We will present you with medication information which is hypothetical but very 
similar to the risks and benefits of MS drugs. We will use two different methods of 
information giving when providing you with information about these pretend 
drugs. The order in which you receive the two different formats may influence 
your understanding (i.e. you may learn things from the first set that help you 
understand the second set of information).  We will mix up the order in which 
different participants receive the two information formats. We will use a process 
called randomisation, which is a bit like tossing a coin, and relies on chance to 
decide each participant’s particular order of formats. To measure your 
understanding, you will then be asked a few questions about the information you 
have received. You will also be asked to choose hypothetically between the two 
medications you were given and be asked a few questions about your confidence 
in that decision. 
 
Before the study task, you will be asked to fill in some questionnaires about your 
mood, fatigue, memory, concentration and attitude towards risk to see how these 
factors may influence your understanding about medication risks and benefits.  
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The whole session may take around 2 to 3 hours. However, breaks will be given 
throughout the study if you feel uncomfortable or tired.  
 
If the research study requires an additional journey to the clinic, reasonable travel 
expenses will be available if agreed in advance.  
 
 
What are the potential benefits of taking part? 
 
We aim to use the information we collect to design and promote better ways of 
presenting drug information to people with MS. You will have helped us do that. 
 
What are the potential risks of taking part? 
 
Potential risks include fatigue, since study sessions may last up to 3 hours. 
However, you may omit any questions you do not wish to answer and are 
encouraged to take regular breaks when taking part. Other similar studies have not 
encountered these problems.  
 
 
How will my data be used and will my taking part in the study be kept 
confidential? 
 
Royal Holloway, University of London is the sponsor for this study based in the 
United Kingdom. We will be using information from you and your medical records 
in order to undertake this study and will act as the data controller for this study. 
This means that we are responsible for looking after your information and using it 
properly. Royal Holloway, University of London will keep identifiable information 
about you for 1 year after the study has finished. 
 
Your rights to access, change or move your information are limited, as we need to 
manage your information in specific ways in order for the research to be reliable 
and accurate. If you withdraw from the study, we will keep the information about 
you that we have already obtained. To safeguard your rights, we will use the 
minimum personally-identifiable information possible. 
 
You can find out more about how we use your information by contacting Professor 
Dawn Langdon, based at Royal Holloway, University of London. 
 
The Royal Free will use your name, NHS number and contact details to contact you 
about the research study, and make sure that relevant information about the study 
is recorded for your care, and to oversee the quality of the study. Individuals from 
Royal Holloway, University of London and regulatory organisations may look at 
your medical and research records to check the accuracy of the research study. The 
Royal Free will pass these details to Royal Holloway, University of London along 
with the information collected from you and your medical records. The only people 
in Royal Holloway, University of London who will have access to information that 
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identifies you will be people who need to contact you to arrange your study visit 
or audit the data collection process. The people who analyse the information will 
not be able to identify you and will not be able to find out your name, NHS number 
or contact details. 
Royal Holloway, University of London will keep identifiable information about you 
from this study for 1 year after the study has finished. 
 
Royal Holloway, University of London will collect information about you for this 
research study from The Royal Free. This information will include your name, NHS 
number, contact details and health information, which is regarded as a special 
category of information. We will use this information to contact you to arrange 
your study visit. 
 
All of the data collected during the study will be kept confidential and will only be 
viewed by authorised researchers in the research team. The study forms you 
complete will not have your name on (we identify you with a unique study code), 
and will be kept in a locked cabinet in a locked room. When the results of the study 
are reported, participants who have taken part will not be identifiable in any way. 
 
Your contact details will be retained at the end of the study in order to send you a 
summary of the findings of the study, if you express that this is something you 
would be interested in receiving.  
 
What will happen to the results of the study? 
 
We plan to present these results at educational conferences for neurologists and 
MS Nurses. We will intend to publish our findings in scientific journals which are 
read by the MS community. Your information will be anonymised in any 
publication and you will not be able to be identified.  
 
 
Who is funding the study? 
 
Royal Holloway, University of London. 
 
 
Who has reviewed the study? 
 
All studies that take part in the NHS are reviewed by an independent group of 
people, called a Research Ethics Committee to protect your safety, rights, wellbeing 
and dignity. This study has been reviewed and given favourable opinion by the 
Health and Social Care Research Ethics Committee B (HSC REC B). 
 
The research has also been approved by the Ethics Committee at Royal Holloway, 
University of London. 
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Contact details 
 
If you have any questions about this study or would like more information about 
this project, please contact: 
 
Elizabeth Donnachie 
Trainee Clinical Psychologist 
Elizabeth.donnachie.2016@live.rhul.ac.uk 
 
 
If taking part in the study raises concerns about your symptoms or care, please 
contact: 
 
Noreen Barker 
MS Clinical Nurse Specialist 
Noreen.barker@nhs.net 
0207 317 7537 
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Volunteers needed for a study to make MS drug 
information easier to understand 
 
We are looking for people with relapsing remitting MS, who are on 
disease-modifying drugs, and aged 18-65. 
 
The study involves information about two hypothetical drugs. The information will 
be presented in two different ways. We want to find out which of the two ways is 
easiest to understand and makes you the most certain about your treatment 
choice. 
 
We plan to use information we get from this study to improve the presentation of 
risk-benefit information about MS drugs, facilitating shared decision-making 
between people with MS and health professionals.  
 
Contact: If you have any questions about this study or would like more 
information about this project, please speak to Noreen Barker (Specialist MS Nurse 
based at the Royal Free), Dr Brenner (Consultant Neurologist based at the Royal 
Free) or contact: 
 
Elizabeth Donnachie, Trainee Clinical Psychologist, 
Elizabeth.donnachie.2016@live.rhul.ac.uk 
Appendix E 
Leaflet 
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Appendix F 
 Consent form 
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2: 
In BRIMMS protocol format: 
“Vettinol” 
“Zafloxtrate” 

Understanding questionnaire 

DCS 

In consultation as usual format: 
“Vettinol” 
“Zafloxtrate” 

Understanding questionnaire 

DCS 
 
Risk measures 
BICAMS 
WTAR 
FSS 
HADS 
 
3: 
In consultation as usual format: 
“Vettinol” 
“Zafloxtrate” 

Understanding questionnaire 

DCS 

In BRIMMS format: 
“Vettinol” 
“Zafloxtrate” 

Understanding questionnaire 

DCS 
 
Risk measures 
BICAMS 
WTAR 
FSS 
HADS 
 
4: 
In consultation as usual format: 
 “Zafloxtrate” 
“Vettinol” 

Understanding questionnaire 

DCS 

In BRIMMS format: 
 “Zafloxtrate” 
“Vettinol” 

Understanding questionnaire 

DCS 
 
Risk measures 
BICAMS 
WTAR 
FSS 
HADS 
 
1: 
In BRIMMS protocol format: 
 “Zafloxtrate” 
“Vettinol” 

Understanding questionnaire 

DCS 

In consultation as usual format: 
 “Zafloxtrate” 
“Vettinol” 

Understanding questionnaire 

DCS 
 
Risk measures 
BICAMS 
WTAR 
FSS 
HADS 
 
Appendix G 
 
Counterbalanced order of presentation of 
assessments 
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Appendix H 
 Hypothetical disease 
 
Trylan’s Disease 
 
 
 
The following information is about a fake 
medical disease, Trylan’s Disease, which is a 
chronic medical condition (a progressive 
condition) and can leads to complications in 
the pancreas and kidneys 
 
Without any treatment and as the disease progresses, a 
patient may experience the following symptoms: 
 Type 2 diabetes: With progression of the disease, 
people are likely to develop Diabetes which would 
require daily management with medications 
 
 Kidney stones: People may frequently experience 
kidney stones over time, which may require surgery. 
Regular monitoring will be required to detect kidney 
stones 
 
 Kidney failure: In the very severe form of the disease, 
people may experience kidney failure and require 
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dialysis. Regular monitoring and scans during the 
condition will be used to detect kidney failure 
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Appendix I 
Example of BRIMMS 
 
 
 
 
 
 
 
 
Zafloxtrate 
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Benefits of taking Zafloxtrate 
 
In a clinical trial, 1000 patients were given 
Zafloxtrate and 1000 patients were given a 
placebo, or a fake pill. 
This was to show the benefits of taking the 
medication on progression of disease. 
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500 
555 
0 100 200 300 400 500 600 700 800 900 1000
Zafloxtrate
Placebo
Placebo vs Zafloxtrate on disease progression - After 1 year 
After 1 year of taking the placebo, the disease 
continues to progress rapidly for 555 people 
out of 1000  
After 1 year of taking Zafloxtrate, the disease 
continues to progress rapidly for 500 people 
out of 1000 
 
So after taking Zafloxtrate for 1 year, disease 
progression slowed down for 55 people  
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479 
672 
0 100 200 300 400 500 600 700 800 900 1000
Zafloxtrate
Placebo
Placebo vs Zafloxtrate on disease progression - After 2 years 
 
After 2 years of taking the placebo, the 
disease continues to progress rapidly for for 
672 people out of 1000 
After 2 years of taking Zafloxtrate, the disease 
continues to progress rapidly for 479 people 
out of 1000 
 
So after taking Zafloxtrate for 2 years, disease 
progression slowed down for 193 people  
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418 
725 
0 100 200 300 400 500 600 700 800 900 1000
Zafloxtrate
Placebo
Placebo vs Zafloxtrate on disease progression - After 5 years 
 
 
 
After 5 years of taking the placebo, the 
disease continues to progress rapidly for 725 
people out of 1000 
After 5 years of taking Zafloxtrate, the disease 
continues to progress rapidly for 418 people 
out of 1000 
 
So after taking Zafloxtrate for 5 years, disease 
progression slowed down for 307 people  
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159 
195 
280 
0 100 200 300 400 500 600 700 800 900 1000
1 year
2 years
5 years
Side-effect of Zafloxtrate - Fever 
 
Side-effect of taking Zafloxtrate 
 
A side-effect of taking Zafloxtrate is fever 
 
After1 year of taking Zafloxtrate, 159 people 
out of 1000 could develop fever 
After 2 years of taking Zafloxtrate, 195 people 
out of 1000 could develop fever 
After 5 years of taking Zafloxtrate, 280 people 
out of 1000 could develop fever 
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124 
212 
351 
0 100 200 300 400 500 600 700 800 900 1000
1 year
2 years
5 years
Side-effect of Zafloxtrate - Back pain 
 
Side-effect of taking Zafloxtrate 
 
Another side-effect of taking Zafloxtrate is 
back pain 
 
After1 year of taking Zafloxtrate, 124 people 
out of 1000 could develop back pain. 
After 2 years of taking Zafloxtrate, 212 people 
out of 1000 could develop back pain. 
After 5 years of taking Zafloxtrate, 351 people 
out of 1000 could develop back pain 
 211 
4 
6 
7 
0 100 200 300 400 500 600 700 800 900 1000
1 year
2 years
5 years
Risk of taking Zafloxtrate - Brain aneurysm 
 
Risks of taking Zafloxtrate 
 
A risk of taking Zafloxtrate is the risk of 
developing a brain aneurysm or blood clots in 
the brain 
 
After 1 year of taking Zafloxtrate, 4 people out 
of 1000 could be at risk of brain aneurysm 
After 2 years of taking Zafloxtrate, 6 people 
out of 1000 could be at risk of brain aneurysm 
After 5 years of taking Zafloxtrate, 7 people 
out of 1000 could be at risk of brain aneurysm 
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Appendix J 
Example of standard consultation 
 
 
 
Zafloxtrate 
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Benefits of taking Zafloxtrate 
 
In a clinical trial, some patients were given 
Zafloxtrate and some were given a placebo, a 
fake pill. 
This showed the benefits of taking the 
medication on progression of disease. 
 
After 1 year of taking Zafloxtrate, the 
progression of disease slowed down by 10% 
compared to patients taking a placebo. 
 
After 2 years of taking Zafloxtrate, the 
progression of disease slowed down by 29%, 
compared to patients taking a placebo. 
 
After 5 years of taking Zafloxtrate, the 
progression of disease slowed down by 42%, 
compared to patients taking a placebo.” 
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Side-effect of taking Zafloxtrate 
 
 
A side-effect of taking Zafloxtrate is fever.  
 
This side-effect is very common, as it effects 
over 1 in 100 people after 1 years, 2 years 
and 5 years of taking Zafloxtrate 
 
  
 
 
 
 
 
Side-effect of taking Zafloxtrate 
 
 
Another side-effect of taking Zafloxtrate is 
back pain.  
 
This side-effect is very common, as it effects 
over 1 in 100 people after 1 years, 2 years 
and 5 years of taking Zafloxtrate. 
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Risks of taking Zafloxtrate 
 
 
A risk of taking Zafloxtrate is the risk of 
developing a brain aneurysm or blood clots in 
the brain 
 
 
After 1 year of taking Zafloxtrate, less than 1 
in 100 people could be at risk of brain 
aneurysm 
 
After 2 years of taking Zafloxtrate, less than 1 
in 100 people could be at risk of brain 
aneurysm 
 
After 5 years of taking Zafloxtrate, less than 1 
in 100 people could be at risk of brain 
aneurysm 
 
 
 
 
 
 
 
 
 
 216 
 
Appendix K 
Understanding questions 
 
 
Understanding questions 
 Zafloxtrate 
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Benefits of taking Zafloxtrate – 1 year 
1. If 1000 people took Zafloxtrate for 1 year, how 
many people will continue to have rapid disease 
progression? 
 99 out of 1000                    
 230 out of 1000                     
 500 out of 1000                    
 822 out of 1000                     
 
2. This question is about the difference between 
people taking Zafloxtrate and people taking the 
placebo. 
After 1 year, how many people had slow disease 
progression after taking Zafloxtrate compared to 
placebo? 
 55 out of 1000                    
 200 out of 1000                     
 380 out of 1000                    
 844 out of 1000                     
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Benefits of taking Zafloxtrate – 2 years 
1. If 1000 people took Zafloxtrate for 2 years, how 
many people will continue to have rapid disease 
progression? 
 82 out of 1000                    
 198 out of 1000                     
 479 out of 1000                    
 811 out of 1000                     
 
2. This question is about the difference between 
people taking Zafloxtrate and people taking the 
placebo. 
After 2 years, how many people had slow disease 
progression after taking Zafloxtrate compared to 
placebo? 
 193 out of 1000                    
 350 out of 1000                     
 600 out of 1000                    
 845 out of 1000                     
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Benefits of taking Zafloxtrate – 5 years 
1. If 1000 people took Zafloxtrate for 5 years, how 
many people will continue to have rapid disease 
progression? 
 112 out of 1000                    
 315 out of 1000                     
 418 out of 1000                    
 798 out of 1000                     
 
2. This question is about the difference between 
people taking Zafloxtrate and people taking the 
placebo. 
After 5 years, how many people had slow disease 
progression after taking Zafloxtrate compared to 
placebo? 
 111 out of 1000                    
 307 out of 1000                     
 598 out of 1000                    
 821 out of 1000                     
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Side-effect of taking Zafloxtrate 
 
1. If 1000 people took Zafloxtrate for 1 year, how many 
people could develop fever? 
 
--------------------------------------------------------------------------- 
 
2. If 1000 people took Zafloxtrate for 2 years, how 
many people could develop fever? 
 
---------------------------------------------------------------------------  
 
 
3. If 1000 people took Zafloxtrate for 5 years, how 
many people could develop fever? 
 
--------------------------------------------------------------------------- 
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Side-effect of taking Zafloxtrate 
 
1. If 1000 people took Zafloxtrate for 1 year, how 
many people could develop back pain? 
 
---------------------------------------------------------------------------  
 
 
2. If 1000 people took Zafloxtrate for 2 years, how 
many people could develop back pain? 
 
---------------------------------------------------------------------------  
 
3. If 1000 people took Zafloxtrate for 5 years, how 
many people could develop back pain? 
 
--------------------------------------------------------------------------- 
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Risk of taking Zafloxtrate 
 
1. If 1000 people took Zafloxtrate for 1 year, how many 
people could be at risk of brain aneurysm? 
 
---------------------------------------------------------------------------  
 
 
2. If 1000 people took Zafloxtrate for 2 years, how 
many people could be at risk of brain aneurysm? 
 
---------------------------------------------------------------------------  
 
 
3. If 1000 people took Zafloxtrate for 5 years, how 
many people could be at risk of brain aneurysm? 
 
---------------------------------------------------------------------------  
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Appendix L 
Decisional Conflict Scale 
Traditional Decisional Conflict Scale (DCS) – Statement Format: 16 item 5 
response categories (O’Connor, 1995) 
My difficulty in making this choice  
A. Which treatment option do you prefer? Please tick one: 
Option 1-Zafloxtrate 
Option 2-Vettinol 
Option 3-No treatment 
Option 4-Unsure  
      B. Considering the option you prefer, please answer the following questions:  
 
Strongly 
Agree  
 
Agree  
 
Neither 
Agree Nor 
Disagree  
 
Disagree  
 
Strongly 
Disagree  
 
1. I know which options are 
available to me.       
2. I know the benefits of each 
option.       
3. I know the risks and side 
effects of each option.       
4. I am clear about which 
benefits matter most to me.       
5. I am clear about which 
risks and side effects matter 
most to me.  
     
6. I am clear about which is 
more important to me (the 
benefits or the risks and side 
effects).  
     
7. I have enough support 
from others to make a 
choice.  
     
8. I am choosing without 
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pressure from others.  
9. I have enough advice to 
make a choice.       
10. I am clear about the best 
choice for me.       
11. I feel sure about what to 
choose.       
12. This decision is easy for 
me to make.       
13. I feel I have made an 
informed choice.       
14. My decision shows what 
is important to me.       
15. I expect to stick with my 
decision.       
16. I am satisfied with my 
decision.       
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Appendix M 
Risk measure 
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Appendix N 
Symbol Digit Modalities Test (SDMT) 
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Appendix O 
 California Verbal Learning Task II (CVLT-II) 
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Appendix P 
Brief Visuospatial Memory Test- Revised (BVMT-R) 
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Appendix Q 
Weschler Test of Adult Reading (WTAR) 
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Appendix R 
Hospital Anxiety and Depression Scale (HADS) 
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Appendix S 
Fatigue Severity Scale (FSS) 
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Appendix T 
Correlations between fatigue, anxiety, depression and cognition 
 
 
A Pearson product-moment correlation was conducted to examine the 
relationship between fatigue, anxiety, depression and cognition. There was a 
significant positive correlation between depression and anxiety, higher levels of 
depression were associated with higher levels of anxiety (r(24)=.79, p<.01). 
There was a significant positive correlation between depression and fatigue, 
higher levels of depression were associated with higher levels of fatigue 
(r(24)=.66, p<.01). There was a significant positive correlation between anxiety 
and fatigue, higher levels of anxiety were associated with higher levels of 
fatigue (r(24)=.56, p<.01). There was a significant negative correlation between 
depression and cognition (r(24)= .-46, p<.05), anxiety and cognition (r(24)=-.55, 
p<.05) and fatigue and cognition (r(24)=-.49, p<.01). That is, higher levels of 
depression, anxiety and fatigue were associated with lower cognition. 
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Appendix U 
Descriptive statistics for demographic variables 
 
 
*WB: White British; BB: Black British; WI: White Irish; AB: Asian British 
**S: Secondary School; C :College; B :Bachelors degree; P: Post-graduate 
***F: Full-time; P: Part-time; MR: Medically Retired; R: Retired 
 
 Gender Age Ethnicity Level of Education Employment Premorbid IQ 
N M:F x̅  
(SD) 
Range WB:BB:WI:AB
* 
S:C:B:P** F:P:MR:R*** x̅  
(SD) 
 
Range Max. total score 
26 7:19 43.38 
(10.32
) 
24-60 19:4:2:1 4:6:8:8 14:3:4:5 101.65 
(14.09) 
 
67-120 120 
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Appendix V 
Descriptive statistics for clinical variables 
 
 
*I:Interferon beats; G:Glatiramer Acetate; T:Teriflunomide; F:Fingolimod; A:Alemtuzumab; D:Dimethyl Fumarate; N:Natalizumab 
 
 
Years since 
diagnosis 
EDSS Current DMD FSS HADS-D HADS-A 
x̅  
(SD) 
Range x̅ 
(SD) 
Range I:G:T:F:A:D:N* x̅ (SD) Range Max. 
total 
score 
x̅  
(SD) 
Range Max. 
total 
score 
x̅  
(SD) 
Range Max. 
total 
score 
9.35 
(6.50) 
1-26 2.81 
(2.45) 
2.5-10 4:2:1:7:3:5:4 37.85 
(18.81) 
9-63 63 4.58 
(3.87) 
0-12 21 7.96 
(4.40) 
2-17 21 
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Appendix W 
Descriptive statistics for cognitive tests 
SDMT CVLT-II BVMT-R 
x̅   
(SD) 
Range Max. total 
score 
x̅  
(SD) 
Range Max. total 
score 
x̅  
(SD) 
Range Max. 
total score 
50.92 
(13.91) 
18-74 110 48.35 
(12.85) 
28-75 80 21.27 
(9.05) 
4-36 36 
 
 
